

## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION  
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 June 1999 (16.06.99)
---

International application No. PCT/US98/19478
---

International filing date (day/month/year) 18 September 1998 (18.09.98)
--

Applicant's or agent's file reference  
UPAP-0263

Priority date (day/month/year)  
18 September 1997 (18.09.97)

Applicant AYYAVOO, Velpandi et al
--------------------------------------

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:  
16 April 1999 (16.04.99)

in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Diana Nissen Telephone No.: (41-22) 338.83.38
---	--



A.D

## PATENT COOPERATION TREATY

PCT

REC'D	28 DEC 1999
WIPO	PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70) 5

Applicant's or agent's file reference UPAP-0263	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US98/19478	International filing date (day/month/year) 18 SEPTEMBER 1998	Priority date (day/month/year) 18 SEPTEMBER 1997
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I  Basis of the report
- II  Priority
- III  Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV  Lack of unity of invention
- V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI  Certain documents cited
- VII  Certain defects in the international application
- VIII  Certain observations on the international application

Date of submission of the demand 16 APRIL 1999	Date of completion of this report 06 DECEMBER 1999
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer LAURIE SCHEINER 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196



**I. Basis of the report**

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

the international application as originally filed.

the description, pages (See Attached) , as originally filed.

pages \_\_\_\_\_, filed with the demand.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

the claims, Nos. (See Attached) , as originally filed.

Nos. \_\_\_\_\_, as amended under Article 19.

Nos. \_\_\_\_\_, filed with the demand.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

the drawings, sheets/fig (See Attached) , as originally filed.

sheets/fig \_\_\_\_\_, filed with the demand.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

the description, pages NONE .

the claims, Nos. NONE .

the drawings, sheets/fig NONE .

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/19478

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>14-17</u>	YES
	Claims <u>1-13 and 18-20</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-20</u>	NO
Industrial Applicability (IA)	Claims <u>1-20</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 1-13 and 18-20 lack novelty under PCT Article 33(2) as being anticipated by Ma et al.

Ma et al. teach isolated attenuated Vif as well as an antibody thereto, and expression of the isolated viral cDNA which encodes the protein. Please see MATERIALS AND METHODS for the construction of HIV-1 clones expressing mutated (attenuated) Vif. Essentially, the HIV-1 Vif protein was attenuated by the substitution of two conserved cysteine residues. Also, please note that PBS reads on a pharmaceutically acceptable carrier or diluent. It is noted that only the functional limitations of the claims were read when objecting over Ma et al. since the SEQ ID NOs. were not considered due to a CRF error.

Claims 14-17 lack an inventive step under PCT Article 33(3) as being obvious over Ma et al.

Ma et al. teach the above. Again, Ma et al. teach attenuation of HIV-1 infectivity by specific inactivating Vif mutants. Moreover, they teach a relative reduction in infectivity when attenuated Vif DNA is cotransfected with WT Vif DNA.

It would have been obvious to one of ordinary skill in the art at the time of the invention to have immunized an infected mammal against a virus by immunizing with the attenuated Vif of Ma et al. since Ma et al. teach a reduction of infectivity of HIV-1 when mutant Vif DNA is cotransfected with WT Vif DNA due to complementation by independent expression of intact Vif in *trans* rather than by homologous recombination. That is, repair (homologous recombination) would most likely increase HIV-1 infectivity, whereas a reduction in infectivity would be expected in a complementation mechanism as taught by Ma et al.

Claims 1-20 meet the criteria set out in PCT Article 33(4), because the prior art does not teach or fairly suggest that the invention would not have industrial applicability.

----- NEW CITATIONS -----

NONE



**Supplemental B x**  
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): A61K 38/00, 39/40, 39/42, 39/38, 39/21, 39/12, 39/395; C07H 21/02, 21/04; C07K 1/00, 16/00; C12P 21/06; C12N 7/04 and US Cl.: 424/134.1, 139.1, 148.1, 160.1, 184.1, 188.1, 199.1, 208.1; 435/69.3, 236; 530/350, 324, 387.1, 389.4; 536/23.1, 23.72

**I. BASIS OF REPORT:**

This report has been drawn on the basis of the description, pages, 1-35 and sequence listing pages 1-32, as originally filed. pages, NONE, filed with the demand.

and additional amendments:

NONE

This report has been drawn on the basis of the claims, numbers, 1-20, as originally filed.

numbers, NONE, as amended under Article 19.

numbers, NONE, filed with the demand.

and additional amendments:

NONE

This report has been drawn on the basis of the drawings, sheets, 1-17, as originally filed.

sheets, NONE, filed with the demand.

and additional amendments:

NONE



## PATENT COOPERATION TREATY

RECEIVED

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

DEC 30 1999

To: MARK DELUCA  
WOODCOCK WASHBURN KURTZ MACKIEWICZ &  
NORRIS LLP  
ONE LIBERTY PLACE - 46TH FLOOR  
PHILADELPHIA, PA 19103

Woodcock Washburn Kurtz  
MacKiewicz & Norris LLP

NOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing  
(day/month/year)

23 DEC 1999


Applicant's or agent's file reference UPAP-0263		IMPORTANT NOTIFICATION	
International application No. PCT/US98/19478	International filing date (day/month/year) 18 SEPTEMBER 1998	Priority Date (day/month/year) 18 SEPTEMBER 1997	
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA			

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer LAURIE SCHEINER Telephone No. (703) 308-0196	
--	---	---



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference UPAP-0263	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US98/19478	International filing date (day/month/year) 18 SEPTEMBER 1998	Priority date (day/month/year) 18 SEPTEMBER 1997
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I  Basis of the report
- II  Priority
- III  Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV  Lack of unity of invention
- V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI  Certain documents cited
- VII  Certain defects in the international application
- VIII  Certain observations on the international application

Date of submission of the demand 16 APRIL 1999	Date of completion of this report 06 DECEMBER 1999
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer LAURIE SCHEINER Telephone No. (703) 308-0196



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/19478

## I. Basis of the report

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

 the international application as originally filed. the description, pages (See Attached) , as originally filed.

pages \_\_\_\_\_, filed with the demand.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

 the claims, Nos. (See Attached) , as originally filed.

Nos. \_\_\_\_\_, as amended under Article 19.

Nos. \_\_\_\_\_, filed with the demand.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

 the drawings, sheets/fig (See Attached) , as originally filed.

sheets/fig \_\_\_\_\_, filed with the demand.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

 the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/19478

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>14-17</u>	YES
	Claims <u>1-13 and 18-20</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-20</u>	NO
Industrial Applicability (IA)	Claims <u>1-20</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 1-13 and 18-20 lack novelty under PCT Article 33(2) as being anticipated by Ma et al.

Ma et al. teach isolated attenuated Vif as well as an antibody thereto, and expression of the isolated viral cDNA which encodes the protein. Please see MATERIALS AND METHODS for the construction of HIV-1 clones expressing mutated (attenuated) Vif. Essentially, the HIV-1 Vif protein was attenuated by the substitution of two conserved cysteine residues. Also, please note that PBS reads on a pharmaceutically acceptable carrier or diluent. It is noted that only the functional limitations of the claims were read when objecting over Ma et al. since the SEQ ID NOs. were not considered due to a CRF error.

Claims 14-17 lack an inventive step under PCT Article 33(3) as being obvious over Ma et al.

Ma et al. teach the above. Again, Ma et al. teach attenuation of HIV-1 infectivity by specific inactivating Vif mutants. Moreover, they teach a relative reduction in infectivity when attenuated Vif DNA is cotransfected with WT Vif DNA.

It would have been obvious to one of ordinary skill in the art at the time of the invention to have immunized an infected mammal against a virus by immunizing with the attenuated Vif of Ma et al. since Ma et al. teach a reduction of infectivity of HIV-1 when mutant Vif DNA is cotransfected with WT Vif DNA due to complementation by independent expression of intact Vif in *trans* rather than by homologous recombination. That is, repair (homologous recombination) would most likely increase HIV-1 infectivity, whereas a reduction in infectivity would be expected in a complementation mechanism as taught by Ma et al.

Claims 1-20 meet the criteria set out in PCT Article 33(4), because the prior art does not teach or fairly suggest that the invention would not have industrial applicability.

**----- NEW CITATIONS -----**

NONE






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 38/00, 39/40, 39/42, 39/38, 39/21, 39/12, 39/395, C07H 21/02, 21/04, C07K 1/00, 16/00, C12P 21/06, C12N 7/04		A1	(11) International Publication Number: <b>WO 99/13896</b>  (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/US98/19478		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 18 September 1998 (18.09.98)			
(30) Priority Data: 60/059,283 18 September 1997 (18.09.97) US 60/060,172 26 September 1997 (26.09.97) US		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): AYYAVOO, Velpandi [IN/US]; 120 Joanna Road, Havertown, PA 19083 (US). NAGASHUNMUGAM, Thanadavarayan [IN/US]; 120 Joanna Road, Havertown, PA 19083 (US). WEINER, David, B. [US/US]; 717 Beacom Lane, Merion Station, PA 19066 (US).			
(74) Agents: ELDERKIN, Dianne, B. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).			

## (54) Title: ATTENUATED VIF DNA IMMUNIZATION CASSETTES FOR GENETIC VACCINES

## (57) Abstract


The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (*vif*) proteins. The nucleic acid molecules of the invention are inserted into recombinant expression vectors and administered to mammals in order to induce a cellular and humoral immune response to the encoded protein product.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



171 P215

## ATTENUATED VIF DNA IMMUNIZATION CASSETTES FOR GENETIC VACCINES

### ACKNOWLEDGMENT OF GOVERNMENT RIGHTS

This invention was made with Government support from the National  
5 Institutes of Health. The Government has certain rights in this invention.

### FIELD OF THE INVENTION

The invention relates to the preparation and use of attenuated, nonfunctional  
HIV *vif* immunization cassettes as genetic vaccines for pathogenic genes.

### BACKGROUND OF THE INVENTION

10 Vaccination and immunization generally refer to the introduction of a non-virulent agent against which an individual's immune system can initiate an immune response which will then be available to defend against challenge by a pathogen. The immune system identifies invading "foreign" compositions and agents primarily by identifying proteins and other large molecules which are not normally present in the individual. The foreign protein  
15 represents a target against which the immune response is made.

The immune system can provide multiple means for eliminating targets that are identified as foreign. These means include humoral and cellular responses which participate in antigen recognition and elimination. Briefly, the humoral response involves B cells which produce antibodies that specifically bind to antigens. There are two arms of the  
20 cellular immune response. The first involves helper T cells which produce cytokines and

elicit participation of additional immune cells in the immune response. The second involves killer T cells, also known as cytotoxic T lymphocytes (CTLs), which are cells capable of recognizing antigens and attacking the antigen including the cell or particle it is attached to.

Vaccination has been singularly responsible for conferring immune protection

5 against several human pathogens. In the search for safe and effective vaccines for immunizing individuals against infective pathogenic agents such as viruses, bacteria, and infective eukaryotic organisms, several strategies have been employed thus far. Each strategy aims to achieve the goal of protecting the individual against pathogen infection by administering to the individual, a target protein associated with the pathogen which can elicit

10 an immune response. Thus, when the individual is challenged by an infective pathogen, the individual's immune system can recognize the protein and mount an effective defense against infection. There are several vaccine strategies for presenting pathogen proteins which include presenting the protein as part of a non-infective or less infective agent or as a discreet protein composition.

15 One strategy for immunizing against infection uses killed or inactivated vaccines to present pathogen proteins to an individual's immune system. In such vaccines, the pathogen is either killed or otherwise inactivated using means such as, for example, heat or chemicals. The administration of killed or inactivated pathogen into an individual presents the pathogen to the individual's immune system in a noninfective form and the individual can

20 thereby mount an immune response against it. Killed or inactivated pathogen vaccines provide protection by directly generating T-helper and humoral immune responses against the pathogenic immunogens. Because the pathogen is killed or otherwise inactivated, there is little threat of infection.

Another method of vaccinating against pathogens is to provide an attenuated

25 vaccine. Attenuated vaccines are essentially live vaccines which exhibit a reduced infectivity. Attenuated vaccines are often produced by passaging several generations of the pathogen through a permissive host until the progeny agents are no longer virulent. By using an attenuated vaccine, an agent that displays limited infectivity may be employed to elicit an immune response against the pathogen. By maintaining a certain level of infectivity, the

30 attenuated vaccine produces a low level infection and elicits a stronger immune response than killed or inactivated vaccines. For example, live attenuated vaccines, such as the poliovirus

and smallpox vaccines, stimulate protective T-helper, T-cytotoxic, and humoral immunities during their nonpathogenic infection of the host.

Another means of immunizing against pathogens is provided by recombinant vaccines. There are two types of recombinant vaccines: one is a pathogen in which specific genes are deleted in order to render the resulting agent non-virulent. Essentially, this type of recombinant vaccine is attenuated by design and requires the administration of an active, non-virulent infective agent which, upon establishing itself in a host, produces or causes to be produced antigens used to elicit the immune response. The second type of recombinant vaccine employs infective non-virulent vectors into which genetic material that encode target antigens is inserted. This type of recombinant vaccine similarly requires the administration of an active infective non-virulent agent which, upon establishing itself in a host, produces or causes to be produced, the antigen used to elicit the immune response. Such vaccines essentially employ infective non-virulent agents to present pathogen antigens that can then serve as targets for an anti-pathogen immune response. For example, the development of vaccinia as an expression system for vaccination has theoretically simplified the safety and development of infectious vaccination strategies with broader T-cell immune responses.

Another method of immunizing against infection uses subunit vaccines. Subunit vaccines generally consist of one or more isolated proteins derived from the pathogen. These proteins act as target antigens against which an immune response may be mounted by an individual. The proteins selected for subunit vaccine are displayed by the pathogen so that upon infection of an individual by the pathogen, the individuals immune system recognizes the pathogen and mounts a defense against it. Because subunit vaccines are not whole infective agents, they are incapable of becoming infective. Thus, they present no risk of undesirable virulent infectivity that is associated with other types of vaccines. It has been reported that recombinant subunit vaccines such as the hepatitis B surface antigen vaccine (HBsAg) stimulate a more specific protective T-helper and humoral immune response against a single antigen. However, the use of this technology to stimulate board protection against diverse pathogens remains to be confirmed.

The construction of effective vaccines is complicated by several factors which include the pathobiology of the pathogen and the specificities of the host immune response. Recently a novel tool for understanding the immune component in these

interactions has become available in the form of genetic immunization or DNA vaccination. Tang, *et al.*, *Nature*, 1992, 356, 152; Fynan, *et al.*, *Proc. Natl. Acad. Sci. USA*, 1993, 90, 11478; Ulmer, *et al.*, *Science*, 1993, 259, 1745; and Wang, *et al.*, *Proc. Natl. Acad. Sci. USA*, 1993, 90, 4156. The ability of this approach was demonstrated to produce broad immune 5 responses against structural and enzymatic gene products of HIV-1 and outlined a strategy for development of a possible prophylactic vaccine for HIV-1. This strategy utilized multiple gene expression cassettes encoding *gag/pol/rev* as well as *env/rev* and accessory gene immunogens. Studies clearly demonstrated that rodents and primates can be successfully immunized with HIV-1 structural and envelope genes. Wang, *et al.*, *Proc. Natl. Acad. Sci.* 10 *USA*, 1993, 90, 4156 and Wang, *et al.*, *DNA Cell Biol.*, 1993, 12, 799. A genetic strategy for construction of immunogen expression cassettes from a pathogenic gene which can be broadly applied in order to use DNA immunogens against a variety of pathogens is needed.

Primate lentiviral genomes contain genes encoding novel regulatory and accessory proteins as well as proteins with structural and enzymatic functions. The regulatory 15 genes, *tat* and *rev*, and the accessory genes, *nef*, *vif*, *vpr*, *vpu*, and *vpx*, are well conserved in many lentiviruses, including HIV and SIV. The well conserved nature of these genes implies that their protein products play a critical role in viral pathogenesis *in vivo*. Initial *in vitro* experiments seemed to demonstrate that *tat* and *rev* were essential for viral replication, while the accessory genes were considered nonessential. Cullen, *et al.*, *Cell*, 1989, 58, 423 and 20 Desrosiers, *AIDS Res. Human Retroviruses*, 1992, 8, 411. Further analyses, however, has revealed that defects within the accessory gene result in severe impairment or delay in viral replication *in vitro* (Gabudza, *et al.*, *J. Virol.*, 1992, 66, 6489 and Gibbs, *et al.*, *AIDS Res. Human Retroviruses*, 1994, 10, 343) and *in vivo* (Aldrovandi, *et al.*, *J. Virol.*, 1996, 70, 1505). Native defective accessory genes have been reported *in vivo* and may be an end 25 product of an effective host immune response. The accessory genes are, therefore, presently considered to be determinants of virus virulence. Trono, *Cell*, 1995, 82, 189. They contain few "hot spots" and may be less susceptible to mutations leading to the production of "escape" virus variants, emphasizing their importance in the viral life cycle. In addition, the protein products of these genes are immunogenic *in vivo*. As a group, they represent twenty percent 30 of the possible anti-viral immune targets. Ameisen, *et al.*, *Int. Conf. AIDS*, 1989, 5, 533 and Lamhamdi-Cherradi, *et al.*, *AIDS*, 1992, 6, 1249. Their immunogenicity and low functional

mutagenicity combine to make the accessory genes attractive elements in the design of future anti-viral immune therapeutics. The production of accessory gene immunogens poses specific immunologic and pathogenic complications for a viral vaccine design, however, due to the role of the accessory gene protein products as determinants of viral virulence. A potential 5 accessory gene-based genetic vaccine would need to be accessible to the host's immune response against native viral accessory gene products without enhancing viral replication. Accordingly, a major goal is to design a safe and effective genetic anti-HIV vaccine, which includes the *vif* (virion infectivity factor) accessory gene as part of a multi-component genetic immunogen.

10 The *vif* gene encodes a 23 kDa late viral protein (*vif*) from a singly spliced, rev-dependent 5 kb transcript. Arya, *et al.*, *Proc. Natl. Acad. Sci. USA*, **1986**, *83*, 2209; Garrett, *et al.*, *J. Virol.*, **1991**, *65*, 1653; Schwartz, *et al.*, *Virol.*, **1991**, *183*, 677; and Sodroski, *et al.*, *Science*, **1986**, *231*, 1549. *Vif* is highly conserved among HIV-1 isolates and is present in other lentiviruses, such as Feline Immunodeficiency Virus (FIV), Bovine 15 Immunodeficiency Virus (BIV), Visna virus, HIV-2, and SIV. Myers, *et al.*, *Human Retrovir. AIDS*, **1991** and Shackett, *et al.*, *Virol.*, **1994**, *204*, 860. Earlier analyses of *in vivo* *vif* genetic variation have shown that most *vif* sequences are intact reading frames and the presence of intact *vif* does not have a correlation with disease status. Sova, *et al.*, *J. Virol.*, **1995**, *69*, 2557 and Wieland, *et al.*, *Virol.*, **1994**, *203*, 43. However, sequential analyses of 20 a region containing *vif*, *vpr*, *vpu*, *tat*, and *rev* genes from a HIV-1 infected long-term progressor revealed the presence of inactivating mutations in 64% of the clones. Michael, *et al.*, *J. Virol.*, **1995**, *69*, 4228. HIV-1 infected subjects have been shown to carry antibodies which recognize recombinant *vif* protein (Kan, *et al.*, *Science*, **1986**, *231*, 1553; Schwander, *et al.*, *J. Med. Virol.*, **1992**, *36*, 142; and Wieland, *et al.*, *AIDS Res. Human Retrovir.*, **1991**, *7*, 861) suggesting that the protein is expressed and is immunogenic during natural infection 25 (Volsky, *et al.*, *Curr. Topics Micro. Immunol.*, **1995**, *193*, 157).

Due to *vif*'s ability to activate viral replication in *trans*, an attenuated genetic vaccine design, similar to those utilized in the production of vaccines derived from toxic viral, bacterial, or parasitic components was employed in the present invention. The sequence 30 variation and immunogenic potential present in *vif* genes derived from HIV-1 infected subjects was analyzed. Prototypic genetic variants were selected and the ability of those

clones to induce humoral and cellular immune responses was studied in animals. The selected *vif* genetic variants were also functionally characterized through transcomplementation assays utilizing cells infected with a *vif*-defective HIV-1 clone. Attenuated, nonfunctional *vif* clones are demonstrated to induce immune responses capable of destroying native pathogen.

## 5 SUMMARY OF THE INVENTION

The present invention relates to a purified attenuated, non-functional *vif* protein.

The present invention relates to a *vif* protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, 10 SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23.

The present invention relates to an isolated nucleic acid molecule comprising 15 a nucleotide sequence encoding an attenuated, non-functional *vif* protein.

The present invention relates to a nucleic acid molecule encoding a *vif* protein which comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, 20 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

The present invention relates to a nucleic acid molecule encoding a *vif* protein which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID 25 NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.

The present invention relates to a pharmaceutical composition comprising the nucleic acid molecule encoding an attenuated, non-functional *vif* protein in a pharmaceutically acceptable carrier or diluent. 30

The present invention relates to a recombinant expression vector comprising a nucleic acid molecule comprising a nucleotide sequence encoding an attenuated, non-functional *vif* protein.

The present invention relates to a host cell comprising a recombinant expression vector comprising a nucleic acid molecule encoding an attenuated, non-functional *vif* protein

The present invention relates to a purified antibody directed against an attenuated, non-functional *vif* protein.

The present invention relates to a method of immunizing a mammal against a virus comprising administering to cells of said mammal, a nucleic acid molecule that comprises a nucleotide sequence that encodes an attenuated, non-functional *vif* protein, wherein said nucleic acid molecule is expressed in said cells.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows a comparison of the deduced amino acid sequences of *vif* derived from transmitter and non-transmitter mothers with well characterized HIV-1 molecular clones PNL43, SF-2, and Zr6. T-#, clones from transmitter subject; N-#, clones from non-transmitter subject; --, identity with the consensus sequence (Con; SEQ ID NO:1); .., represents gap; \*, a stop codon.

Figure 2 shows a 10% SDS-PAGE of immunoprecipitates. Expression of HIV-1 *vif* clones derived from transmitter and non-transmitter mothers. *Vif* expression plasmids were used for coupled *in vitro* transcription/translation according to the manufacturer's instructions (Promega). Immunoprecipitation of the *in vitro* translated proteins was performed with *vif* antiserum as described herein. The designation of the *vif* clones is indicated on the top. The clone numbers designated with T-\*\* and N-\*\* are derived from the transmitter and non-transmitter mothers respectively. pCVif is the *vif* expression plasmid of HIV-1<sub>SF2</sub>.

Figures 3A and 3B show the results of an enzyme linked immunoabsorbent assay (ELISA) of anti-*vif* antibody responses in mice after immunization with a DNA construct expressing *vif*. Mouse sera was diluted in blocking buffer at a dilution of 1:500 and

assayed as described herein. In Figure 3A, mice were immunized with 50  $\mu$ g of DNA. In Figure 3B, mice were immunized with 100  $\mu$ g of DNA per injection.

Figure 4 shows the results of a chromium release assay whereby lysis of murine targets (p815) expressing *vif* protein by splenocytes from mice immunized with *vif* expression constructs. p815 cells ( $1 \times 10^5$ /ml) were infected with vaccinia expressing *vif* (VV:gag) and incubated for 16 hours to express the Vif protein. The target cells were labeled with  $^{51}\text{Cr}$  for 1-2 hours and used to incubate the stimulated splenocytes for 6 hours. Specific lysis (%) was calculated according to the formula described herein.

Figures 5A, 5B, 5C and 5D show the results of a chromium release assay whereby lysis of HeLa CD4+/D<sup>d</sup> cells infected with clinical HIV-1 isolate by splenocytes from mice immunized with *vif* expression cassette. HeLa CD4+/D<sup>d</sup> cells ( $10^6$ ) were infected with cell-free HIV-1 clinical isolate followed by a week incubation to allow the cells to infect and express viral proteins. One week postinfection, the target cells were labeled with  $^{51}\text{Cr}$  for 1-2 hours and used to incubate the stimulated splenocytes for 6 hours. Specific lysis (%) was calculated according to the formula described herein.

Figure 6 shows the results of a proliferation assay showing activation and T cell proliferative response to recombinant Vif. Recombinant Vif (10  $\mu$ g/ml) was plated in each well to stimulate proliferation of T cells. Lectin PHA (10  $\mu$ g/ml) was used as a polyclonal stimulator positive control. Stimulation index was calculated as the level of radioactivity detected from the cells stimulated with specific protein divided by the level detected from the cells in media. Lanes 1a and 1b are from mice immunized with 50 and 100  $\mu$ g of pCVif; Lanes 2a and 2b are from mice immunized with 50 and 100  $\mu$ g of clone T-35; Lanes 2a and 2b are from mice immunized with 50 and 100  $\mu$ g of clone N-15.

Figures 7A-7F show the amino acid sequences of preferred attenuated, non-functional *vif* proteins of the present invention.

Figures 8A-8E show the nucleotide sequences of preferred attenuated, non-functional *vif* proteins of the present invention.

## DETAILED DESCRIPTION OF THE INVENTION

One of the major goals of AIDS research is the development of a vaccine against the HIV-1 virus. An effective vaccine should elicit strong humoral response along

with an efficient and broad CTL response. This task is complicated because of the genetic heterogeneity of the HIV-1 virus. HIV-1 reverse transcriptase (RT) is prone to error and lacks the ability to proof-read, resulting in a mutation rate of  $10^{-4}$  per cycle per genome. Dougherty, *et al.*, *J. Virol.*, **62**, 2817. HIV-1 genome sequence variation has been observed

5 in viruses isolated from different individuals as well as in virus isolated from a single person at different time points. Fisher, *et al.*, *Nature*, **1988**, *334*, 444 and Meyerhans, *et al.*, *Cell*, **1989**, *58*, 901. Based upon a large number of sequence analysis data, it is apparent that the structural genes *env*, *gag* and *pol* are the major target for mutations which lead to escape-variant viruses in patients by changing the neutralizing antibody and/or CTL epitopes.

10 Pircher, *et al.*, *Nature*, **1990**, *346*, 629; Reitz, *et al.*, *Cell*, **1988**, *54*, 57; and Wolfs, *et al.*, *Virol.*, **1991**, *185*, 195. Despite this, earlier experiments have indicated that structural and enzymatic genes of HIV-1 can be used successfully as nucleic acid-based vaccines in different animal models (Wang, *et al.*, *Proc. Natl. Acad. Sci. USA*, **1993**, *90*, 4156; and Wang, *et al.*, *AIDS*, **1995**, *9* (Suppl A), S159) and prophylactic as well as therapeutic studies for DNA

15 vaccines have commenced. The present invention is directed to development of *vif*, a HIV-1 accessory gene, as an immunogen cassette. When used in concert with other HIV-1 genes a broad immune response against all viral components may be induced, thus mimicking many aspects of the immune responses induced by a live attenuated vaccine.

In the present invention, induction of *vif*-specific humoral and cellular immune

20 responses in mice have been observed to directly correlate with the concentration of DNA injected and number of boosts. Similar results were observed in T-cell proliferation and CTL assays, demonstrating that *vif* genes are immunogenic *in vivo*. *Vif* is known to present in both soluble and membrane associated form. Goncalves, *et al.*, *J. Virol.*, **1994**, *68*, 704. Although anti-*vif* antibodies and *vif*-specific CTL responses have been shown in HIV-1 positive

25 patients, epitopes involved in the presentation of *vif* to the immune system have not yet been defined. Lamhamdi-Cherradi, *et al.*, *AIDS*, **1992**, *6*, 1249. How *vif* becomes exposed to the humoral immune system is unclear in these studies. The observed different immune response in the clones of the present invention suggest that the mutations in T-35, N-15 and pCVif may be associated with changes in antibody/CTL responses.

30 It is significant to note that some the point mutations present in all the T or N derived clones indicate that these mutations may be responsible for the difference in

complementation and/or immune responses observed. Further mutational analysis of *vif* help resolve answer the regions involved in complementation. Proposed sites of *vif* activity include viral DNA synthesis, gpl20 synthesis and transport, and gag processing. Borman, *et al.*, *J. Virol.*, 1995, 69, 2058; Sakai, *et al.*, *J. Virol.*, 1993, 67, 1663; and Von Schwedler, *et al.*, *J. Virol.*, 1993, 67, 4945. Transcomplementation experiments with *vif*-defective HIV-1 provirus and wild-type HIV-1 *vif*-expressing cell lines indicate that *vif* acts at a late stage in virus replication/maturation and that *vif* transcomplementation occurs across HIV-1 strains. Blanc, *et al.*, *Virol.*, 1993, 193, 186 and Hevey, *et al.*, *Virus Res.*, 1994, 33, 269. Earlier experiments have shown that sera from the nontransmitter subject (N1) contains a high antibody titer against envelope protein and nonreplicating virus; whereas sera from the transmitter patient (T1) contains very low antibody titers against envelop proteins and highly replicating virus. Velpandi, *et al.*, *DNA Cell Biol.*, 1996, 15, 571. These results correlate with the trans-complementation results observed in the present invention.

The present invention relates to isolated nucleic acid molecules comprising a nucleotide sequence encoding an attenuated, non-functional *vif* protein. As used herein, the term "attenuated, non-functional *vif* protein" is meant to refer to *vif* proteins that have no or reduced virion infectivity function compared to wild-type *vif*. In some embodiments of the invention, the nucleic acid molecules encode an attenuated, non-functional *vif* protein wherein the nucleotide sequence comprises deletions, additions, a point mutation(s), multiple substitutions, or introduction of a stop codon to render a shortened protein. In preferred embodiments of the invention, the isolated nucleic acid molecules of the invention encode a *vif* protein comprising the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In other preferred embodiments of the invention, the isolated nucleic acid molecules encode a *vif* protein and comprise a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID

NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.

The nucleic acid molecules of the invention may be obtained from patients infected with the human immunodeficiency virus as described below in the Examples.

5 Alternatively, the nucleic acid molecules of the invention may be prepared using the wild-type *vif* nucleotide sequence. The *vif* expression plasmid, pCVif, contains the *vif* gene from the well-characterized HIV-1 molecular clone, pHXB2, under the control of the cytomegalovirus (CMV) immediate early promoter, within the backbone plasmid, pRc/CMV (Invitrogen, San Diego, CA) as described in Nagashunmugam, *et al.*, *DNA Cell Biol.*, 1996,

10 15,353, incorporated herein by reference. This nucleic acid molecule may be used to prepare additional nucleic acid molecules encoding attenuated, non-functional *vif* proteins.

A number of methods can be used to design specific mutations in wild-type nucleic acid molecules to produce nucleic acid molecules encoding attenuated, non-functional *vif* proteins. For example, oligonucleotide-mediated mutagenesis is commonly used to add,

15 delete, or substitute nucleotides in a segment of DNA whose sequence is known. Such methods are taught in, for example, Sambrook *et al.*, *Molecular Cloning a Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989), pages 15.51 to 15.73, which is incorporated herein by reference. Briefly, the protocol for oligonucleotide-mediated mutagenesis involves the following steps: 1) cloning of an appropriate fragment of DNA,

20 such as the *vif* nucleotide sequence from the pCVif expression plasmid, into a bacteriophage M13 vector; 2) preparation of single-stranded DNA from the recombinant bacteriophage M13; 3) design and synthesis of mutagenic oligonucleotides; 4) hybridization of the mutagenic oligonucleotides to the target DNA; 5) extension of the hybridized oligonucleotide by DNA polymerase; 6) transfection of susceptible bacteria; 7) screening of bacteriophage

25 plaques for those carrying the desired mutation; 8) preparation of single-stranded DNA from the mutagenized recombinant bacteriophage; 9) confirmation by sequencing that the mutagenized bacteriophage M13 DNA carries the desired mutation and no other mutation;

10) recovery of the mutated fragment of DNA from the double-stranded replicative form of the recombinant bacteriophage M13; and 11) substitution of the mutagenized fragment for

30 the corresponding segment of wild-type DNA in the desired expression vector.

Design and synthesis of the mutagenic oligonucleotides, which are tailored to the desired mutation in the nucleic acid molecule encoding *vif*, is described in detail in, for example, Sambrook et al., *Molecular Cloning a Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989), pages 15.54 to 15.56, which is incorporated herein by reference. For 5 example, to substitute, add, or delete a single nucleotide into the wild-type *vif* nucleotide sequence, oligonucleotides of about 17-19 nucleotides in length which carry the mismatched nucleotide at the center or at one of the two nucleotide positions immediately 3' of the center are prepared. To substitute, add, or delete two or more contiguous nucleotides into the wild-type *vif* nucleotide sequence, oligonucleotides of about 25 or more nucleotides in length are 10 prepared. These oligonucleotides comprise about 12 to 15 perfectly matched nucleotides on either side of the central looped-out region which contains the added or substituted nucleotides, or represents the portion of the wild-type DNA that is looped out. Using the strategy described above, one skilled in the art can prepare nucleic acid molecules having deletions, additions, substitutions, or premature stop codons, which encode attenuated, non- 15 functional *vif* proteins. Oligonucleotide-mediated mutagenesis procedures are widely known to those skilled in the art.

Alternately, the nucleic acid molecules of the invention can be prepared using DNA synthesizers by standard DNA methodology. One skilled in the art readily understands that the genetic code is degenerate and, therefore, could prepare numerous DNA sequences 20 encoding the same protein. In addition, one skilled in the art readily understands that amino acids can be substituted by other amino acids such that conservative substitutions are made. Accordingly, one skilled in the art can prepare nucleic acid molecules of the invention encoding attenuated, non-functional *vif* proteins.

Preferred nucleic acid molecules of the invention encode attenuated, non- 25 functional *vif* proteins having the amino acid (a.a.) and nucleotide sequences (nt.) (represented by particular SEQ ID Numbers) in Table 1. The specific amino acid sequences are shown in Figure 1 and Figures 7A-7F. The specific nucleotide sequences are shown in Figures 8A-8E.

Table 1

Vif Protein	SEQ ID NO:		Vif Protein	SEQ ID NO:	
	a.a.	nt.		a.a.	nt.
N13	4	27	Vif Protein	T3	14
N15	5	28		T4	15
N17	6	29		T35	16
N22	7	30		T37	17
N23	8	31		T38	18
N24	9	32		T39	19
N26	10	33		T40	20
N27	11	34		T42	21
N29	12	35		T43	22
N30	13	36		T44	23
					46

The present invention also relates to vectors or recombinant expression vectors that comprise a nucleotide sequence that encodes an attenuated, non-functional *vif* protein.

15 As used herein, the term "recombinant expression vector" is meant to refer to a plasmid, phage, viral particle or other vector which, when introduced into an appropriate host, contains the necessary genetic elements to direct expression of the coding sequence that encodes an attenuated, non-functional *vif* protein. In some embodiments of the invention, the vector or recombinant expression vector encodes an attenuated, non-functional *vif* protein wherein the

20 nucleotide sequence comprises deletions, additions, point mutation(s), multiple substitutions, or introduction of a stop codon to render a shortened protein. In preferred embodiments of the invention, the vectors or recombinant expression vectors of the invention encode a *vif* protein comprising the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In other preferred embodiments of the invention, the vectors or recombinant expression vectors of the invention comprise a nucleic

25

acid molecule encoding a *vif* protein which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, 5 SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.

One having ordinary skill in the art can isolate the nucleic acid molecule that encodes an attenuated, non-functional *vif* protein and insert it into an expression vector using standard techniques and readily available starting materials. The coding sequence is operably linked to the necessary regulatory sequences. Expression vectors are well known and readily 10 available. Examples of expression vectors include plasmids, phages, viral vectors and other nucleic acid molecules or nucleic acid molecule containing vehicles useful to transform host cells and facilitate expression of coding sequences. The recombinant expression vectors of the invention are useful for transforming hosts which express an attenuated, non-functional *vif* protein.

15 The present invention also relates to a host cell that comprises the recombinant expression vector that includes a nucleotide sequence that encodes an attenuated, non-functional *vif* protein. In some embodiments of the invention, the host cell comprises the vector or recombinant expression vector that encodes an attenuated, non-functional *vif* protein wherein the nucleotide sequence comprises deletions, additions, point mutation(s), multiple 20 substitutions, or introduction of a stop codon to render a shortened protein. In preferred embodiments of the invention, the host cells comprises vectors or recombinant expression vectors that encode a *vif* protein comprising the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID 25 NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. In other preferred embodiments of the invention, the host cell comprises vectors that comprise a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, 30 SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45

and SEQ ID NO:46. Host cells for use in well known recombinant expression systems for production of proteins are well known and readily available.

The most commonly used prokaryotic system remains *E. coli*, although other systems such as *B. subtilis* and *Pseudomonas* are also useful. Suitable control sequences for 5 prokaryotic systems include both constitutive and inducible promoters including the *lac* promoter, the *trp* promoter, hybrid promoters such as tac promoter, the *lambda* phage P1 promoter. In general, foreign proteins may be produced in these hosts either as fusion or mature proteins. When the desired sequences are produced as mature proteins, the sequence produced may be preceded by a methionine which is not necessarily efficiently removed. 10 Accordingly, the peptides and proteins claimed herein may be preceded by an N-terminal Met when produced in bacteria. Moreover, constructs may be made wherein the coding sequence for the peptide is preceded by an operable signal peptide which results in the secretion of the protein. When produced in prokaryotic hosts in this manner, the signal sequence is removed upon secretion. Examples of prokaryotic host cells include bacteria cells such as *E. coli*, and 15 yeast cells such as *S. cerevisiae*.

A wide variety of eukaryotic hosts are also now available for production of recombinant foreign proteins. As in bacteria, eukaryotic hosts may be transformed with expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein. Eukaryotic systems have the 20 additional advantage that they are able to process introns which may occur in the genomic sequences encoding proteins of higher organisms. Eukaryotic systems also provide a variety of processing mechanisms which result in, for example, glycosylation, carboxy-terminal amidation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth. Commonly used eukaryotic systems include, but are not limited to, yeast, fungal 25 cells, insect cells, mammalian cells, avian cells, and cells of higher plants. In preferred embodiments of the invention insect cells such as *S. frugiperda*, non-human mammalian tissue culture cells chinese hamster ovary (CHO) cells and human tissue culture cells such as HeLa cells are used as host cells. Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and 30 enhancers, as e.g. the baculovirus polyhedron promoter. As above, promoters can be either

constitutive or inducible. For example, in mammalian systems, the mouse metallothionein promoter can be induced by the addition of heavy metal ions.

In some embodiments, for example, one having ordinary skill in the art can, using well known techniques, insert DNA molecules into a commercially available expression 5 vector for use in well known expression systems. For example, the commercially available plasmid pSE420 (Invitrogen, San Diego, CA) may be used for production of an attenuated, non-functional *vif* protein in *E. coli*. The commercially available plasmid pYES2 (Invitrogen, San Diego, CA) may, for example, be used for production in *S. cerevisiae* strains of yeast. The commercially available MAXBAC™ complete baculovirus expression system 10 (Invitrogen, San Diego, CA) may, for example, be used for production in insect cells. The commercially available plasmid pcDNA I or pcDNA3 (Invitrogen, San Diego, CA) may, for example, be used for production in mammalian cells such as Chinese Hamster Ovary cells. One having ordinary skill in the art can use these commercial expression vectors and systems or others to produce an attenuated, non-functional *vif* protein by routine techniques and 15 readily available starting materials. See e.g., Sambrook et al., *Molecular Cloning a Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989), which is incorporated herein by reference.

One having ordinary skill in the art may use other commercially available expression vectors and systems or produce vectors using well known methods and readily 20 available starting materials. Expression systems containing the requisite control sequences, such as promoters and polyadenylation signals, and preferably enhancers, are readily available and known in the art for a variety of hosts. See e.g., Sambrook et al., *Molecular Cloning a Laboratory Manual*, Second Ed. Cold Spring Harbor Press (1989).

Examples of genetic constructs include the attenuated, non-functional *vif* 25 protein coding sequence operably linked to a promoter that is functional in the cell line into which the constructs are transfected. Examples of constitutive promoters include promoters from cytomegalovirus or SV40. Examples of inducible promoters include mouse mammary leukemia virus or metallothionein promoters. Those having ordinary skill in the art can readily produce genetic constructs useful for transfecting with cells with DNA that encodes 30 an attenuated, non-functional *vif* protein from readily available starting materials. Such gene constructs are useful for the production of an attenuated, non-functional *vif* protein.

Nucleic acid molecules that encode an attenuated, non-functional *vif* protein may be delivered to cells using any one of a variety of delivery components, such as recombinant viral expression vectors or other suitable delivery means, so as to affect their introduction and expression in compatible host cells. In general, viral vectors may be DNA 5 viruses such as recombinant adenoviruses and recombinant vaccinia viruses or RNA viruses such as recombinant retroviruses. Other recombinant vectors include recombinant prokaryotes which can infect cells and express recombinant genes. In addition to recombinant vectors, other delivery components are also contemplated such as encapsulation in liposomes, transferrin-mediated transfection and other receptor-mediated means. The invention is 10 intended to include such other forms of expression vectors and other suitable delivery means which serve equivalent functions and which become known in the art subsequently hereto.

In a preferred embodiment of the present invention, DNA is delivered to competent host cells by means of an adenovirus. One skilled in the art would readily understand this technique of delivering DNA to a host cell by such means. Although the 15 invention preferably includes adenovirus, the invention is intended to include any virus which serves equivalent functions.

In another preferred embodiment of the present invention, RNA is delivered to competent host cells by means of a retrovirus. One skilled in the art would readily understand this technique of delivering RNA to a host cell by such means. Any retrovirus 20 which serves to express the protein encoded by the RNA is intended to be included in the present invention.

In another preferred embodiment of the present invention, nucleic acid is delivered through folate receptor means. The nucleic acid sequence to be delivered to a host cell is linked to polylysine and the complex is delivered to the tumor cell by means of the 25 folate receptor. U.S. Patent 5,108,921 issued April 28, 1992 to Low *et al.*, which is incorporated herein by reference, describes such delivery components.

The present invention is also related to purified attenuated, non-functional *vif* proteins. The *vif* proteins of the invention have deletions, additions, point mutation(s), multiple substitutions, or introduction of stop codons to produce peptides that are attenuated 30 and non-functional compared to wild type *vif* protein. In preferred embodiments of the invention, the attenuated, non-functional *vif* proteins of the invention comprise an amino acid

sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ 5 ID NO:23. In other preferred embodiments of the invention, the attenuated, non-functional *vif* proteins of the invention consist of an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, 10 SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. The *vif* proteins of the invention may be prepared by routine means using readily available starting materials as described above.

The particulars for the construction of expression systems suitable for desired hosts are known to those in the art and are described above. For recombinant production of 15 the protein, the DNA encoding it is suitably ligated into the expression vector of choice and then used to transform the compatible host which is then cultured and maintained under conditions wherein expression of the foreign gene takes place. The proteins of the present invention thus produced are recovered from the culture, either by lysing the cells or from the culture medium as appropriate and known to those in the art. One having ordinary skill in 20 the art can, using well known techniques, isolate an attenuated, non-functional *vif* protein that is produced using such expression systems. Methods of purifying an attenuated, non-functional *vif* protein from natural sources using antibodies which specifically bind to an attenuated, non-functional *vif* protein may be equally applied to purifying an attenuated, non-functional *vif* protein produced by recombinant DNA methodology.

25 In addition to producing these proteins by recombinant techniques, automated amino acid synthesizers may also be employed to produce *vpr* protein. It should be further noted that if the proteins herein are made synthetically, substitution by amino acids which are not encoded by the gene may also be made. Alternative residues include, for example, the  $\omega$  amino acids of the formula  $\text{H}_2\text{N}(\text{CH}_2)_n\text{COOH}$  wherein n is 2-6. These are neutral, nonpolar 30 amino acids, as are sarcosine (Sar), t-butylalanine (t-BuAla), t-butylglycine (t-BuGly), N-methyl isoleucine (N-MeIle), and norleucine (Nleu). Phenylglycine, for example, can be

substituted for Trp, Tyr or Phe, an aromatic neutral amino acid; citrulline (Cit) and methionine sulfoxide (MSO) are polar but neutral, cyclohexyl alanine (Cha) is neutral and nonpolar, cysteic acid (Cya) is acidic, and ornithine (Orn) is basic. The conformation conferring properties of the proline residues may be obtained if one or more of these is 5 substituted by hydroxyproline (Hyp).

Pharmaceutical compositions according to the invention comprise a pharmaceutically acceptable carrier in combination with either an attenuated, non-functional *vif* protein or a nucleic acid molecule of the invention encoding the same. In preferred embodiments of the invention, the pharmaceutical composition comprises a recombinant 10 expression vector that encodes a *vif* protein comprising the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

15 In other preferred embodiments of the invention, the pharmaceutical composition comprises a nucleic acid molecule encoding a *vif* protein which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, 20 SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46. Pharmaceutical formulations are well known and pharmaceutical compositions comprising the compounds of the invention may be routinely formulated by one having ordinary skill in the art. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field, which is 25 incorporated herein by reference in its entirety.

The present invention also relates to an injectable pharmaceutical composition that comprises a pharmaceutically acceptable carrier and a compound of the present invention. The compound of the invention is preferably sterile and combined with a sterile pharmaceutical carrier. In some embodiments, for example, the compounds of the invention 30 can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable vehicle. Examples of such vehicles are water, saline,

Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation is sterilized by commonly used 5 techniques.

An injectable composition may comprise a compound of the invention in a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol. The injectable must be sterile and free of pyrogens.

10 Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets.

15 Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Compositions for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

20 The pharmaceutical compositions of the present invention may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous 25 drip, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intrathecal or intraventricular administration.

30 Dosage varies depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art.

According to the invention, the pharmaceutical composition comprising a nucleic acid molecule that encodes a *vif* protein of the invention may be administered directly into the individual or delivered *ex vivo* into removed cells of the individual which are reimplanted after administration. By either route, the genetic material is introduced into cells which are present in the body of the individual. Preferred routes of administration include intramuscular, intraperitoneal, intradermal and subcutaneous injection. Alternatively, the pharmaceutical composition may be introduced by various means into cells that are removed from the individual. Such means include, for example, transfection, electroporation and microprojectile bombardment. After the nucleic acid molecule is taken up by the cells, they are reimplanted into the individual.

The pharmaceutical compositions according to this aspect of the present invention comprise about 0.1 to about 1000 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 1 to about 500 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 25 to about 250 micrograms of DNA. Most preferably, the pharmaceutical compositions contain about 100 micrograms DNA.

The pharmaceutical compositions according to this aspect of the present invention are formulated according to the mode of administration to be used. One having ordinary skill in the art can readily formulate a nucleic acid molecule that encodes a *vif* protein of the invention. In cases where intramuscular injection is the chosen mode of administration, an isotonic formulation is used. Generally, additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. Isotonic solutions such as phosphate buffered saline may be used. Stabilizers include gelatin and albumin.

DNA-based pharmaceutical agents are being developed as a new generation of vaccines. DNA therapeutics are typically plasmids that contain one or more DNA vaccines are typically plasmids which contain one or more genes from a particular pathogen or undesirable cell. Once injected, the coding sequence of the DNA vaccine is expressed in the patient or vaccinee as protein products and an immune response against the protein product is induced. Examples of protocols for delivering DNA which can be adapted for use with the present invention are described in U.S. Patent No. 5,593,972 issued January 14, 1997 to Weiner, U.S. Patent No. 5,589,466 issued December 14, 1996 to Felgner et al., U.S. Patent

Number 4,945,050 issued July 31, 1990 to Sanford et al., U.S. Patent Number 5,036,006 issued July 30, 1991 to Sanford et al., PCT publication serial number WO 90/11092, PCT publication serial number WO 93/17706, PCT publication serial number WO 93/23552, and PCT publication serial number WO 94/16737 which are each incorporated herein by reference.

5 In preferred embodiments of the invention, pharmaceutical compositions comprising nucleic acid molecule comprising a nucleotide sequence encoding an attenuated, non-functional *vif* protein is administered to a mammal by the methods described above in order to induce a humoral and/or a cellular immune response to *vif* protein. In other 10 embodiments of the invention, the pharmaceutical compositions of the invention can be co-administered with additional compounds. Such additional compounds include, for example, different viral proteins or nucleic acid molecules encoding a different viral proteins. The different viral proteins include, for example, *gag*, *pol*, *env*, *vpr*, *vpu*, and *tat*, and the like. Such elicited immune responses are protective against HIV or related animal viruses.

15 The present invention is also directed to antibodies directed against an attenuated, non-functional *vif* protein. As used herein, the term "antibody" is meant to refer to complete, intact antibodies, and Fab fragments and F(ab)<sub>2</sub> fragments thereof. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies. In some embodiments, the antibodies 20 specifically bind to an epitope of *vif* or attenuated, non-functional *vif*. Antibodies that bind to an epitope are useful to isolate and purify that protein from both natural sources or recombinant expression systems using well known techniques such as affinity chromatography. Such antibodies are useful to detect the presence of such protein in a sample and to determine if cells are expressing the protein.

25 Hybridomas which produce antibodies that bind to *vif* protein, and the antibodies themselves, are useful in the isolation and purification of *vif* and attenuated, non-functional *vif* and protein complexes that include *vif* or attenuated, non-functional *vif*. In addition, antibodies may be specific inhibitors of *vif* activity. Antibodies which specifically bind to *vif* or attenuated, non-functional *vif* may be used to purify the protein from natural 30 sources using well known techniques and readily available starting materials. Such antibodies

may also be used to purify the protein from material present when producing the protein by recombinant DNA methodology.

The production of antibodies and the protein structures of complete, intact antibodies, Fab fragments and F(ab)<sub>2</sub> fragments and the organization of the genetic sequences that encode such molecules are well known and are described, for example, in Harlow, E. and D. Lane (1988) *ANTIBODIES: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. which is incorporated herein by reference. Briefly, for example, *vif* or attenuated, non-functional *vif*, or an immunogenic fragment thereof, is injected into mice. The spleen of the mouse is removed, the spleen cells are isolated and fused with immortalized mouse cells. The hybrid cells, or hybridomas, are cultured and those cells which secrete antibodies are selected. The antibodies are analyzed and, if found to specifically bind to *vif* or attenuated, non-functional *vif*, the hybridoma which produces them is cultured to produce a continuous supply of antibodies.

The present invention is further illustrated by the following examples, which are not intended to be limiting in any way. All references cited in the present application are incorporated in their entirety.

## EXAMPLES

### Example 1: Patients

Virus from one HIV-1 positive transmitter mother (T1) and one HIV-1 positive non-transmitter mother (N1) were used in the present invention. Peripheral blood lymphocytes (PBLs) obtained during the subject's third trimester were provided by the Mother Infant Cohort Study, Viral Epidemiology Branch, NCI (Rockville, MD). A follow up examination was performed on the subjects and their offspring in order to determine transmission status.

### 25 Example 2: HIV-1 Isolation

Infected primary lymphocytes were co-cultivated with PHA-stimulated normal donor lymphocytes for 2 weeks. Virus production was monitored by: 1) measuring the levels of intracellular HIV-1 reverse transcriptase (RT) (Velpandi, *et al.*, *J. Virol. Meth.*, 1990, 29, 291; incorporated herein by reference) and 2) measuring the amount of HIV-1 p24 antigen

released into the medium using a p24 antigen kit (Coulter Corporation), used according to the manufacturer's guidelines.

### **Example 3: DNA Preparation And PCR Amplification**

High molecular weight (genomic) DNA was prepared from the infected PBLs 5 and amplifies through PCR technology as described in Velpandi, *et al.*, *J. Virol. Meth.*, 1990, 29, 291, incorporated herein by reference. Briefly, the PCR mixture contained 5 to 10 µg of genomic DNA, 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 10 mM Tris/HCl (pH 8.0), 800 µM dNTPs, 2.5 units Taq polymerase, 20 pmol oligonucleotide primers and double de-ionized water (ddH<sub>2</sub>O) in a final volume of 100 µl. Reaction temperatures and cycling times were: 94 °C-denaturing 10 (1 minute), 55 °C-annealing (1.5 minutes) and 72 °C-extension (2 minutes). The cycle was repeated 35 times. The primer sequences are as follows: Vif(+) 5'-**GAAAGCTTATGGAAAACAGATGGCAG-3'** (5046-5065) (SEQ ID NO:2); and Vif(-) 5'-**GCAAAGCTTCATTGTATGGCTC-3'** (5609-5626) (SEQ ID NO:3). The primers were tagged with a HindIII restriction site (in bold) for cloning purposes.

### **15 Example 4: Cloning And Sequencing**

PCR-amplified product was used for cloning as described in Velpandi, *et al.*, *DNA Cell Biol.*, 1996, 15, 571, incorporated herein by reference. Plasmid DNA positive for the *vif* gene was purified by mini preparations (Qiagen, CA) and quantitated by spectrophotometry in preparation for sequencing of the insert. Sequencing reactions were 20 performed using an ABT automated sequencer and Dye Deoxy reactions (Applied Biosystems, Foster City, CA).

### **Example 5: Sequence Analysis**

Sequence alignments were constructed using the Genetics Computer Group Sequence Analysis software package acquired through the Medical School Computer Facility 25 of the University of Pennsylvania VAX system. Homology comparisons of amino acid sequences were carried out by sequence alignment programs.

**Example 6: Construction Of Vif-Defective Provirus**

HIV-1 proviral DNA, pZr6, was used to construct a *vif* deletion mutant as described in Nagashunmugam, *et al.*, *DNA Cell Biol.*, 1996, 15, 353, incorporated herein by reference. The resulting proviral clone, p911, contains an 80 amino acid deletion in the *vif* gene which does not affect the 3' reading frame. Briefly, HIV-1 proviral DNA pZr6 was derived from primary blood lymphocytes infected with HIV<sub>Zr6</sub> as described in Srinivasan, *et al.*, *Gene*, 1987, 52, 71-82, incorporated herein by reference in its entirety. A deletion was introduced into pZr6 to prepare p911. The mutant was constructed so as not to interfere with the upstream *pol* gene or the downstream *vpr* gene. Plasmid pZr6 contains two *Nde*I sites in the *vif* gene at nucleotide positions 476 and 716. Srinivasan, *et al.*, *Gene*, 1987, 52, 71-82. The *Nde*I fragment (477-716) was deleted from pZr6 and the ends were religated to construct p911, an in-frame mutant that has 80 amino acids deleted in the central region of the *vif* protein.

**Example 7: Construction Of Vif Expression Vectors**

The *vif* expression plasmid, pCVif, contains the *vif* gene from the well-characterized HIV-1 molecular clone, pHXB2, under the control of the cytomegalovirus (CMV) immediate early promoter, within the backbone plasmid, pRc/CMV (Invitrogen, San Diego, CA) as described in Nagashunmugam, *et al.*, *DNA Cell Biol.*, 1996, 15, 353, incorporated herein by reference. The *vif* genes from the maternal samples were cloned into the Invitrogen expression vector, pCDNA3, under the control of the CMV promoter. The *vif* reading frames were verified through sequence analysis using the forward primer, T7, and the reverse primer, SP6. Briefly, to construct a *vif* expression vector (pCVif), an *Eco* RI-*Eco* RI 1.1 kb fragment from pHXB2 (map coordinates 4,647-5,742; Ratner, *et al.*, *Nature*, 1985, 313, 277-284, incorporated herein by reference in its entirety) was cloned under the control of the cytomegalovirus immediate early promoter into plasmid pCDNA3 obtained from Invitrogen. This fragment also contains flanking sequences from parts of the *pol* and *vpr* genes, which are not transcriptionally active as shown in a similar construct by Blanc, *et al.* (*Virology*, 1993, 193, 186-192).

**Example 8: In Vitro Translation Of Vif**

*In vitro* transcription and translation was performed on 1  $\mu$ g of *vif* expression construct DNA using T7 RNA polymerase according to the manufacturer's instructions (Promega, Madison, WI). Five (5)  $\mu$ l of the *in vitro* translation reaction products were 5 combined with 500  $\mu$ l of radioimmunoprecipitation assay buffer and immunoprecipitated with rabbit anti-*vif* antiserum as described. Mahalingam, *et al.*, *Virol.*, 1995, 214, 647.

**Example 9: Cells**

Rhabdomyosarcoma (RD) cells, obtained from the American Type Culture Collection (ATCC), were grown in a monolayer at 37°C in 5% CO<sub>2</sub> in Dulbecco's modified 10 Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin, 1% streptomycin and 1% L-glutamine. Lymphocytoid cell lines obtained from ATCC were maintained as suspension cultures in RPMI 1640 medium, supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and L-glutamine (540  $\mu$ g/ml) at 37°C with 5% CO<sub>2</sub>. Phytohemagglutinin-stimulated (10  $\mu$ g/ml) PBLs were maintained in RPMI 1640 medium 15 containing 10% T-cell growth factor.

**Example 10: Immunization Of Mice With Vif Constructs**

For immunization experiments in mice, 3 different *vif* constructs were used. The *vif* clones selected were T-35 (from transmitter), N-15 (from non-transmitter) and pCVif (*vif* gene of HIV-1<sub>SF-2</sub>). pCDNA3 vector DNA was used as a negative control. In order to 20 enhance DNA uptake, the quadriceps muscles of BALB/c mice were injected with 100  $\mu$ l of 0.25% bupivacaine 48 hours before DNA injection. Fifty (50) or 100  $\mu$ g of each *vif* expression plasmid was injected in a final volume of 100  $\mu$ l into each of 4 mice. The animals 25 were boosted 3 times at two week intervals.

**Example 11: ELISA Binding Of Mouse Serum To rvif Protein**

25 ELISA was performed on mouse serum as described in Wang, *et al.*, *AIDS*, 1995, 9 (Suppl A), S159. Briefly, ELISA plates were coated with recombinant *vif* (rvif) protein at concentration of 100 ng/well for the binding assays. Mouse sera were diluted (1:100 and 1:500) in blocking buffer, tagged with anti-mouse IgG conjugated to horseradish

peroxidase (HRP) and detected by TMBBlue substrate. The non-specific binding and the prebled sera binding were subtracted from the specific binding of the DNA injected animal sera.

**Example 12: CTL Assay Using Vaccinia Expressing *vif***

5 DNA injected mice were sacrificed 7 weeks after the first immunization, and their spleens were removed for CTL and T-cell proliferation assays as described in Wang, *et al.*, *DNA Cell Biol.*, 1993, 12, 799. Briefly, P815 cells infected with *vif*-expressing vaccinia (VV:gag kindly provided by NIH AIDS Reagent and Reference Program) were used as target cells. Ten (10)  $\mu$ Ci of  $\text{Na}_2\text{CrO}_4$  ( $^{51}\text{Cr}$ , 534 mCi/mg, Dupont Co.) was added to  $1 \times 10^6$ /ml

10 target cells which were subsequently incubated for 2 hours at room temperature. The cells were then washed 3 times with serum-free media and diluted to a volume of  $1 \times 10^5$  cells/ml in RPMI 1640/10% calf serum. The effector spleen cells were washed once, resuspended and diluted to a concentration of  $1 \times 10^7$  cells/ml of RPMI medium. 1:2 serial dilutions were made from this stock cell solution ( $5 \times 10^6$ ,  $2.5 \times 10^6$  and  $1.25 \times 10^6$  cells/ml). One hundred (100)

15  $\mu$ l of these effector cell solutions were aliquoted into a 96-well microliter flat bottom plate. One hundred (100)  $\mu$ l of target cell solution was added to each well. The resultant effector to target cell ratios were 100:1, 50:1, 25:1 and 12.5:1. In order to determine the spontaneous or maximum chromium release, respectively, target cells were mixed with either 100  $\mu$ l of media alone or 1% Triton-X. The effector and target cells were then incubated at 37°C in a

20 5%  $\text{CO}_2$  incubator for 5 hours. A 100  $\mu$ l aliquot of supernatant was removed from each well, and the amount of  $^{51}\text{Cr}$  release was measured in a gamma counter. The formula for calculation of the specific CTL release is below:  $100 \times [( \text{experimental release} - \text{spontaneous release}) / \text{maximum release} - \text{spontaneous release} ]$ . Note: maximum release was determined by lysis of target cells in 1% Triton X-100.

25 **Example 13: CTL Assay Using Clinical HIV-1 Isolates**

HeLa CD4+ cells expressing mouse MHC-I were infected with HIV-1 clinical isolates and used as target cells in the CTL assay. The CTL assay was performed as described in Chada, *et al.*, *J. Virol.*, 1993, 67, 3409.

**Example 14: T Cell Proliferation Assay**

Assays were performed in triplicate. Splenocytes were isolated as discussed above, resuspended in RPMI 1640 and diluted to a concentration of  $3.3 \times 10^6$  cells/ml. A 150  $\mu$ l aliquot was immediately added to each well of a 96-well microtiter flat bottom plate.

5    Fifty (50)  $\mu$ l of protein or peptide was added to each well to final concentrations of 10.0, 1.0 or 0.1 mg/ml. The cells were incubated at 37°C in a 5% CO<sub>2</sub> incubator for 3 days. One (1)  $\mu$ Ci of tritiated thymidine was added to each well, and the cells were incubated overnight under the same conditions. The cells were harvested using automated cell harvester (Tomtec, Orange, CT) and the amount of incorporated tritiated thymidine was measured in a beta

10   counter. In order to ensure that the cells were healthy, 5 mg/ml of PHA was used as a non-specific stimulator in a positive control sample.

**Example 15: Transcomplementation Of vif Defective Proviral DNA With vif Genes From Maternal Samples**

RD cells ( $1 \times 10^6$ ) were co-transfected with 10  $\mu$ g of a vif defective proviral clone, p911, and 10  $\mu$ g pCVif or vif expression plasmid from transmitter or non-transmitter subjects using lipofectin from Boehringer Mannheim (Indianapolis, IN). The co-transfected cells were washed after an 8 hour incubation and resuspended in DMEM media. Culture supernatant was collected after a 72 hour incubation, centrifuged to remove cell debris, passed through a 0.45  $\mu$ m filter, and assayed for p24 production (Coulter Corporation). PBMCs ( $1 \times 10^7$ ) were infected with an amount of virus equivalent to 100 ng of p24 antigen. Virus-inoculated cells were incubated for 4-6 hours at 37°C and 5% CO<sub>2</sub>, washed 3 times with PBS and resuspended in 10 ml of fresh RPMI 1640. An aliquot of the culture supernatant was collected every 3 days in order to quantitate virus production by measuring the amount of p24 antigen released into the medium.

**25   Example 16: Characterization Of Viruses Isolated From Patients**

The HIV-1 positive transmitter and non-transmitter mothers included in the present invention were selected from an AIDS cohort study. The mother and the non-transmitter mother are referred to as T1 and N1, respectively. The clinical status of the subjects and the replication kinetics of their viral isolates are presented in Table 2.

Uncultured lymphocytes from each subject were used in order to obtain wild-type sequences unmodified by *in vitro* selection conditions. In PBMC co-cultivation assays, T1 viral samples replicated very well in normal donor PBLs; whereas N1 viral samples did not replicate in either primary lymphocytes or macrophages.

5

**Table 2**

Subject	Clinical Stage	PCR	Virus Coculture in PBMC	Infection in CD4+ Cell Lines
Transmitter	Asymptomatic	+++	+++	+++
Non-Transmitter	Asymptomatic	++	---	---

**Example 17: Sequence Variation Of *Vif* Gene In Vivo**

10 In order to investigate the genetic variability of the *vif* gene in these subjects, ten clones from each subject were sequenced and computer-aligned by degree of homology. The nucleotide sequences were then translated into protein sequences. Deduced amino acid sequences were used in the final comparison, since not all nucleotide sequence changes resulted in amino acid sequence changes. The aligned amino acid sequences from these 15 patients are shown in Figure 1. Clone numbers with the designations, 'T' and 'N' represent variants isolated from transmitter and non-transmitter mothers, respectively. Sequence alignment revealed that each subject had a unique and highly conserved set of sequences within their virus pool. Most of the nucleotide changes were point mutations which generally resulted in substitutions, versus duplications or insertions, within the protein sequence. Three 20 clones encoded attenuated proteins. Clone T-42 had a 5 amino acid deletion at its 3' end due to a premature stop codon. Clone N-13 had two stop codons (positions 31 and 41) and clone T-4 had a single stop codon (position 77), each of which was introduced within a set of three nucleotides, keeping the reading frame intact 3' to the mutation. The fact that the majority (17 of 20) of the clones encode full-length sequences suggests that there are few defective *vif* 25 genes present within these patients' viral pools. It is interesting to note that most of the *vif* point mutations are present in the 5' portion of the gene rather than in the 3' region.

Significant differences were found between clones at positions 20, 27, 31, 36, 37, 45, 60, 74, 127, 136, 140 and 150.

In order to determine the nature and the sequence variation of *vif* gene *in vivo*, we cloned and analyzed *vif* variants present in uncultured PBMCs from HIV-1 positive subjects. Analysis of 20 different *vif* sequences from two subjects (10 from each subject) revealed that *vif* is highly conserved (approximately 90%) within a particular patient at a given time point. Although, Wieland, et al. (*Virol.*, 1994, 203, 43) reported that the 3' portion of the *vif* gene is highly variable, the results of the present invention indicate that the 5' portion (aa 20-85) is more variable and the 3' portion is well-conserved. In support of the results herein, previous mutagenesis experiments have shown that the C terminus of *vif* (aa 171 to 192) is essential for stable association of *vif* with membranes. Goncalves, et al., *J. Virol.*, 1994, 68, 704. Among the 20 sequences we analyzed, only two clones had premature stop codons indicating that 90% of *vif* genes isolated were intact *in vivo*. This result, along, with previously published data, suggests that a complete *vif* gene is essential for viral replication *in vivo*. Gabudza, et al., *J. Virol.*, 1992, 66, 6489; and Sova, et al., *J. Virol.*, 1995, 69, 2557.

The 20 deduced *vif* protein sequences from these clones exhibited 75% conservation (25% variation) over the entire (192 aa) length. In particular, two antigenic domains, aa 87-94 (IEWRKKRY) (SEQ ID NO: 24) and aa 172-178 (DRWNKPQ) (SEQ ID NO: 25), recognized by HIV-1 positive sera (Wieland, et al., *AIDS Res. Human Retrovir.*, 1991, 7, 861) are well conserved in all 20 clones. The well-conserved nature of these two regions may be responsible for the cross antigenic properties exhibited by these clones. In addition, a sequence which is conserved in 34/38 lentivirus *vif*, SLQYLA (144-149)(SEQ ID NO: 26) (Oberste, et al., *Virus Genes*, 1992, 6, 95), is also conserved in each of the 20 *vif* clones sequenced in the present invention. In previous studies, computer alignment analyses has shown that amino acids 21 to 30, 103 to 115 and 142 to 150 of *vif* are highly conserved among HIV-1, HIV-2 and SIV. Myers, et al., *Human Retrovir. AIDS*, 1988. Clones analyzed in the present invention, however, were generally conserved sequences within aa 103-115 and aa 142-150, but not within aa 21-30. *Vif* protein has been characterized as a cysteine protease with Cys 114 marking its active site and His 48 considered to be important for activity. Guy,

*et al.*, *J. Virol.*, 1991, 65, 1325. In the sequences of the present invention, Cys 114, as well as Cys 133 (the only other cystine in vif) and His 48, were well conserved.

Phylogenetic tree analysis (data not shown) found 3 major families within the 20 patient clones. Ninety (90%) percent of N-derived clones formed a family and 80% of T-derived clones formed a family while the remaining clones, N-30, T-3 and T-38, exhibited greater diversity and formed a Separate group (data not shown). When distance comparison was performed, intrapatient variation between the transmitter clones was 12%, versus a variation of 10% between non-transmitter clones. The similarity between the subjects' variant clones and the established laboratory molecular clones, HIV<sub>SF-2</sub>, HIV<sub>NL43</sub> and 10 HIV<sub>Zr6</sub>, was also evaluated. The subject isolates shared a higher degree of homology with other clones within their transmitter status group than with any of the laboratory-maintained viral isolates. Based upon their sequence variation, 4 clones from each patient were selected for preliminary translation/immunization experiments (see below).

Phylogenetic tree analysis also illustrated that, in spite of intra-patient 15 variation, clones from the transmitter and nontransmitter subjects clustered separately. *In vitro* transcription/translation of 8 constructs (four from each subject) resulted in the expression of a 23 KDa protein, except in the case of clone N-13 which has a premature stop codon. This suggests that the various mutations present in these vif constructs did not affect the expression kinetics and stability of the protein.

20 **Example 18: Expression Of Vif Clones**

*In vitro* transcription/translation was performed upon 5 clones from each group in order to assess their levels of vif expression. Results are presented in Fig. 2. The products from the *in vitro* translation reactions were immunoprecipitated with vif antiserum and subjected to gel electrophoresis. pCVif (full length vif from HIV-1 strain SF2) and p911 (vif 25 mutant) provirus were used as a positive and negative control, respectively. *In vitro* translation with pCVif and each of the full length vif expression plasmids produced a 23 kDa protein; whereas clones p911 and N-13 did not result a protein product of 23 kDa size, probably due to the presence of premature stop codons. Two (2) clones from each subject group were selected for further evaluation, based upon similar serological characteristics (data 30 not shown). The patient clones selected as representatives from each group were T-35 (from

transmitter) and N-15 (from non-transmitter). Each of these clones contain mutations characteristic of their particular group and represent the highest level of diversity within these groups. It is interesting to note that mutations within clone N-15 are dispersed throughout the full length gene; whereas mutations within clone T-35 are clustered at the 5' end of the 5 gene.

**Example 19: Induction Of Humoral Responses *In Vivo***

Specific anti-vif immune responses were apparent in sera collected from mice immunized with T-35, N-15 and pCVif expression plasmids, but not in sera from mice immunized by pcDNA3 vector alone. The induction of immune response correlated with 10 DNA injection concentration, as well as the number and time interval between boosts. Sera from 4 mice injected with either 50 or 100 µg of *vif*/DNA had specific reactivity to vif protein when measured by ELISA (Fig. 3). Induction of the humoral response was dose-and time-dependent. Injection of 50 µg of DNA induced an immune response detectable by ELISA at 15 days following the first injection. This response increased after subsequent boosts, 15 reaching a maximum level 45 days after 2 boosts (Panel A). Injection with 100 µg of DNA induced a response that reached a maximum level only 28 days after a single boost (Panel B). In addition, the antibody response can be elevated 219 days after the three injections with a single boost of DNA (data not shown). The level of antibody response varied between vif clones. Most importantly, the non-transmitter clone, N-15, induced a higher serological 20 response than the transmitter clone, T-38, or pCVif. This suggests that non-transmitter vif is capable of inducing a more efficient B-T helper dependent response than transmitter vif in this strain of mice.

**Example 20: Induction Of Cellular Responses *In Vivo* Using Vaccinia Expressing Vif**

Four mice, each immunized with one of the vif constructs, were given an 25 additional boost 15 days after first injection. Two mice were subsequently sacrificed and their splenocytes were used in a cytotoxic T cell (CTL) assay. p815 cells infected with vif-expressing vaccinia were used as target cells. Non-specific lysis by splenocytes from vif DNA immunized and naive mice was measured using p815 cells infected with non-vif-expressing vaccinia as target cells. Specific target lysis is presented in Fig. 4. The level of

specific CTL activity varied between the *vif* constructs. Splenocytes from mice immunized with clone pCVif exhibited 45% lysis at a effector: target ratio of 100:1. Clones T-35 and N-15 exhibited 17 and 12% lysis, respectively, at the same ratio. These results clearly demonstrate that *vif* DNA immunization induces specific CTL responses. The differences 5 in the levels of CTL activity induced by *vif* gene inoculation between the various patient clones may be due to mutations within the CTL epitopes expressed by vaccine targets or differences in immune responsiveness in this haplotype.

**Example 21: Evaluation Of Cellular Responses *In Vivo* Using Human Targets Infected With A Clinical HIV-1 Isolate**

10 In order to evaluate the ability of the *vif* clones to induce lysis of virally infected targets, we used HIV-1 infectable HeLa CD4/D<sup>d</sup> cells which express both the CD4 receptor and the murine class I H-2D<sup>d</sup> restriction element, as targets in the CTL assay. These cells were infected with an HIV-1 isolate derived from a symptomatic AIDS patient for 7 days. Figure 5 (A-D) represents CTL assay results. Splenocytes obtained from mice injected 15 with each of the DNA constructs exhibited *vif*-specific lysis. Clones T-35, N-15 and pCVif presented with 27, 26 and 24% lysis, respectively, at an effector:target ratio of 50:1. All three clones exhibited 20% lysis at a ratio of 25:1. This demonstrates that a cellular immune response against native HIV-1 isolates can be generated through genetic vaccination with *vif* expression vectors.

20 **Example 22: Induction Of Antigen Specific T-Cell Proliferation**

Specific T-cell proliferation responses against HIV-1 *vif* protein were also studied in DNA-immunized animals. Lymphocytes from *vif*-immunized mice demonstrated a significant proliferative response against rvif protein. Figure 6 illustrates the proliferation index of different *vif* constructs versus DNA injection concentrations. The results show that 25 the MHC class II-dependent T<sub>h</sub> (helper) cell response is dose dependent. For each construct, the stimulation index is almost 2-fold higher in mice injected with 100 µg of *vif* DNA than in mice injected with 50 µg of *vif* DNA. Comparison of the three different *vif* constructs also indicates that, at each injection concentration, clone T-35 induces a higher stimulation index than either N-15 or pCVif.

**Example 23: Transcomplementation of HIV-1 Vif- Provirus With Vif Expression Plasmids**

As expected, transient transfection of RD cells with HIV-1 (*vif*-) proviral DNA and *vif* expression plasmids did not reveal any differences in virus production between T-derived, N-derived or control plasmids (data not shown). Any differences in *vif* function would be demonstrated at the level of new infection. When rescued virus was used to infect primary lymphocytes, however, a significant difference was observed in virus pathogenesis between T- and N-derived and control plasmids (Table 3). The *vif*-negative proviral clone (p911) alone was unable to infect primary PBLs as cell-free virus. When trans-complemented virus (p911 + pCVif) was used to infect the PBLs, infectivity was five-fold less than that of wild-type virus. In contrast, each of the T-derived clones tested were able to rescue the (*vif*-) mutant (approximately 100% positive virus control). However, none of the N-derived clones were able to efficiently infect PBLs as cell-free virus. Therefore, N-15 and similar N-derived clones were able to induce anti-HIV immune responses in mice in the absence of functionality.

**Table 3**

Samples	DNA Used to Derive Viruses for Infection	Amount of p24 Released (ng/ml)
Proviral Clone	pZr6	101,846
Vif Mutant	p911	60
Vif Mutant + pCVif	p911 + pCVif	22,679
Vif Mutant + Transmitter Clones	p911 + T1-40 p911 + T1-37 p911 + T1-35 p911 + T1-38	21,896 17,230 19,470 81,570
Vif Mutant + Non-Transmitter Clones	p911 + N1-13 p911 + N1-15 p911 + N1-17 p911 + N1-27 p911 + N1-30	520 530 1,090 1,277 715

RD cells were transfected with 10 µg of pZr6, vif mutant p911, p911 and vif expression plasmids from different patient samples. Virus pools were prepared from supernatant collected 72 hours after transfection. Virus equivalent to 100 ng of p24 antigen was subsequently used to infect 10 x 10<sup>6</sup> PBMCs. Infection was monitored by p24 antigen

5 production.

#### **Example 24: Observations**

N-derived clones were attenuated in their ability to transcomplement vif defective HIV-1 provirus. One of the clones analyzed, N-15, was also immunologically functional and capable of generating an immune response against wild-type HIV-1 virus. A

10 non-functional yet immunogenic clone, such as N-15 in the present invention, could be an effective component of a genetic vaccine directed against HIV-1. It has been shown in the present invention that vif alone can generate an effective response against native HIV-1 virus *in vitro*. Such immunogens could be useful in a therapeutic setting to target the immune response against native vif expressing viruses. While it is likely that escape variants can

15 occur viruses expressing defective vifs due to this selection might now exhibit attenuated *in vivo* growth kinetics. In a similar manner a prophylactic vaccine which includes vif could serve to both limit viral escape and contribute to lowering the viral set point during the early infection events.

**What is Claimed is:**

1. An isolated, attenuated, non-functional *vif* protein.
2. The protein of claim 1 wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23.
3. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an attenuated, non-functional *vif* protein.
4. The nucleic acid molecule of claim 3 wherein said nucleic acid molecule comprises a nucleotide sequence which encodes an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.
5. The nucleic acid molecule of claim 3 wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.
6. A pharmaceutical composition comprising a protein of claim 1 in a pharmaceutically acceptable carrier or diluent.

7. A pharmaceutical composition comprising a nucleic acid molecule of claim 3 in a pharmaceutically acceptable carrier or diluent.
8. A recombinant expression vector comprising a nucleic acid molecule of claim 3.
- 5 9. The recombinant expression vector of claim 8 wherein said nucleic acid molecule comprises a nucleotide sequence which encodes an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, 10 SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.
10. A host cell comprising a recombinant expression vector comprising a nucleic acid molecule of claim 3.
11. The host cell of claim 8 wherein said nucleic acid molecule comprises a nucleotide sequence which encodes an amino acid sequence selected from the group 15 consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.
12. A purified antibody directed against an attenuated, non-functional *vif* protein.
- 20 13. The antibody of claim 12 wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ 25 ID NO:23.

14. A method of immunizing a mammal against a virus comprising administering to cells of said mammal, a nucleic acid molecule that comprises a nucleotide sequence that encodes an attenuated, non-functional *vif* protein, wherein said nucleic acid molecule is expressed in said cells.

5 15. The method of claim 14 wherein said nucleic acid molecule comprises a nucleotide sequence which encodes an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, 10 SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

16. The method of claim 14 wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, 15 SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.

17. The method of claim 14 wherein said virus is selected from the group consisting of human immunodeficiency virus, feline immunodeficiency virus, bovine immunodeficiency virus, Visna virus, and simian immunodeficiency virus.

20 18. A plasmid comprising a nucleotide sequence encoding an isolated, attenuated, non-functional *vif* protein.

19. The plasmid of claim 18 wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23.

20. The plasmid of claim 18 wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41,  
5 SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46.



1	N24	-----	y	r	e	q	e	v	-----	t	-----	h
	N27	-----	y	r	e	q	e	v	-----	t	-----	h
	N26	-----	y	r	e	q	e	v	-----	t	-----	h
	N15	-----	y	r	e	q	r	e	-----	t	-----	h
	N17	-----	y	r	e	q	e	-----	t	-----	t	-----
	N23	-----	y	r	e	q	e	-----	t	-----	t	-----
	N29	-----	y	r	e-n	hr	e	-----	t	-----	t	-----
	N13	i	-----	y	*	e	*	q	e	s	t	-----
	N22	-----	y	r-q	e-n	h	e	-ap-	t	-----	t	-----
	T39	-----	a	kk	-----	kk	-----	-----	a	-----	a	-----
	T44	-----	a	kk	-----	q	-----	-----	a	-----	a	-----
	T43	-----	a	kk	-----	kk	-----	-----	a	-----	a	-----
	T37	e	-----	a	-----	kk	-----	-----	v	-----	a	-----
	T40	-----	t-a	-----	kk	-----	-----	-----	v	-----	a	-----
	T35	-----	a	i-f	-----	kk	n	-----	vt-p	-----	g	y-a
	T4	-----	a	-----	-----	t-s	g	c	-----	s-a	*	v-t
	T3	-----	a	-----	-----	kk	-----	ta	-----	g	k-av	s-q-a-qv-r-lp
	T38	-----	a	-----	n-kk	-----	v q-ta	-----	g-qia	s-da	-----	a
	T42	-----	a	-----	kk-n	-----	r	-----	-----	a	-----	r
Con	Menymyiv	WYDWRITI	WISLKHIM	VSKKAR	WYF	REHESHPK	VSEVENHPIG	DARLETTIW	GLH	GERKH	LGQGSTAR	KRUSTQMDP
101	N24	-----	h	r-s	s	i	-----	-----	a	-----	-----	-----
	N27	-----	h	r-s	s	i	-----	-----	a	-----	-----	-----
	N26	h	-----	h	r-s	i	-----	-----	-----	-----	-----	-----
	N15	-----	h	r-s	s	i	-----	-----	-----	-----	-----	-----
	N17	-----	h	r-s	s	i	-----	-----	-----	-----	-----	-----
	N23	h	-----	h	r-s	i	-----	-----	-----	-----	-----	-----
	N29	-----	h	r-s	s	i	-----	-----	-----	-----	-----	-----
	N13	-----	h	r-s	s	i	-----	-----	a	-----	-----	-----
	N22	-----	h	r-s	s	i	-----	-----	-----	-----	-----	-----
	T39	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T44	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T43	-----	g	-----	-----	-----	g	-----	-----	-----	-----	-----
	T37	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T40	t	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T35	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T4	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T3	v	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T38	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
	T42	t	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
Con	OLADQHILY	YDFDFSESAI	RAALGURS	PREEYQAHN	KVCSLOYLAL	AAALITKTK	PPLPSVURKLT	ERWKPKPT	KCHRGCS-HM	NGH-	te-aig-	dt..

FIGURE 1






FIG.2



FIGURE 3B





FIGURE 3A








FIGURE 4



FIGURE 5B




FIGURE 5A




FIGURE 5D





FIGURE 5C








FIGURE 6



**FIGURE 7A****1. vif-N13.pep**

MENRWQVIIIV WQVDRMRIRT WNSLVKYHMY \*SKKKAREWFY \*HHYQSPHPK  
VSSEVHIPLE DARLEITTSFW GLHTGERDWH LGQGVSTIEWR KRRYSTHVDP  
DLADQLIHLHY YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLOYLAI  
AALITPKKIK PPLASVRKLT EDRWNKPQKT KGHRGSHIMN GH\*

**2. vif-N15.pep**

MENRWQVMIV WQVDRMRIRT WNSLVKYHMY RSKKKAREWFY RHHYQSPHPR  
VSSEVHIPLE DARLEITTYW GLHTGERDWH LGQGVSTIEWR KRRYSTQVDP  
DLADQLIHLHY YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLOYLAI  
AALITPKKIK PPLPSVRKLT EDRWNKPQKT KGHRGSHIMN GH\*

**3. vif-N17.pep**

MENRWQVMIV WQVDRMRIRT WNSLVKYHMY RSKKKAREWFY RHHYQSPHPK  
VSSEVHIPLE DARLEITTYW GLHTGERDWH LGQGVSTIEWR KRRYSTQVDP  
DLADQLIHLHY YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLOYLAI  
AALITPKKIK PPLPSVRKLT EDRWNKPQKT KGHRGSHIMN GH\*



## FIGURE 7B

4. **vif-N22.pep**

MENRQVMIV WQVDRMRIRT WNSLVITYHMY RSQKAREWFN RHHYHSPHPK  
VSSEVHIPLE DARLAIPFW GLHTGERDWH LGQGVSIWR KRRYSTQVDP  
DLADQLIHL YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI  
AALITPKKIK PPLPSVRKLT EDRANKPQKT KGHRGSHIMN GH\*

5. **vif-N24.Pep**

MENRQVMIV WQVDRMRIRT WNSLVKYHMY RSKKAREWFY RHHYQSPHPK  
VSSEVHIPLE DARLVITTYW GLHTGERDWH LGQGVSIWR KRRYSTHVDP  
DLADQLIHL YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI  
AALITPKKIK PPLASVRKLT EDRANKPQKT KGHRGSHIMN GH\*

6. **vif-N26.pep**

MENRQVMIV WQVDRMRIRT WNSLVKYHMY RSKKAREWFY RHHYQSPHPK  
VSSEVHIPLE DARLVITTYW GLHTGERDWH LGQGVSIWR KRRYSTQVDP  
DLADHLIHL YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI  
AALITPKKIK PPLASVRKLT EDRANKPQKT KGHRGSHIMN GH\*

7. **vif-N27.pep**

MENRQVMIV WQVDRMRIRT WNSLVKYHMY RSKKAREWFY RHHYQSPHPK  
VSSEVHIPLE DARLVITTFW GLHTGERDWH LGQGVSIWR KRRYSTHVDP  
DLADQLIHL YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI



## FIGURE 7C

AALITPKKIK PPLPSVRKLT EDRWINKPQKT KGHRGSHIMN GH\*

**8. vif-N29.pep**

MENRWQVMIV WQVDRMRIRT WNSLVKYHMY RSKKAREWFN RHHYHRPHPK  
VSSEVHIPLE DARLETTTFW GLHTGERDWH LGQGVSVIEWR KRRYSTQVDP  
DLADQLIHLY YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI  
AALITPKKIK PPLPSVRKLT EDRWINKPQKT KGHRGSHIMN GH\*

**9. vif-N30.**

MENRWQVMIV WQVDRMRIRT WNSLVKYHMY RSOKEREWFN RHHYHSPHPE  
QSSTAHIPLV DGRLEKIAW SLDIGEGVWH RGHRVSVIEWR KRRYSTQVDP  
DLVDQLIHLY YFDCFSESAI RKAILGHRVS PRCEYRAGHS KVGSLQYLAI  
AALITPKKIK PPLPSVRKLT EDRWINKPQKT KGHRGSHIMN GH\*

**vif-T3.pep**

MENRWQVMIV WQVDRMRIRT WNSLVKHHMY VSKKAKKWFY RHHYESPHPK  
VSSTAHIPLG DGRLEKIAW SLOAGDGVWH RGHPVSIEWR KRRYSTQVDP  
DLVDQLIHLY YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDRWINKPQKT KGHRGSHIMN GH\*

**vif-T35.pep**



## FIGURE 7D

MENRWQVMIV WQVDRMRIRA WNSLVKHHY FSKKAKKWFY RHHYESPHN  
VSSEVH~~I~~PLG DARLVITPYW GLHGERDWY LAQGV~~S~~IEWR KRRYSTQVDP  
DLADQLIHL~~Y~~ YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT ED~~R~~W~~N~~KPQKT KGHRGSHIMN GH\*

**vif-T37.pep**

MENRWEVMIV WEVDRMRIRA WNSLVKHHY VS~~K~~AKKWFY RHHYESPHPK  
VSSEVH~~I~~PLG DARLVITTYW GLHAGERDW~~H~~ LGQGV~~S~~IEWR KRRYSTQVDP  
DLADQLIHL~~Y~~ YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT ED~~R~~W~~N~~KPQKT KGHRGSHIMN GH\*

**vif-T38.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHY VS~~K~~AKKWFY RHHYDSPHPV  
QSSTAH~~I~~PLG DGRLOKIAFW SLDAGERDW~~H~~ LGQGV~~S~~IEWR KRRYSTQVDP  
DLADQLIHL~~Y~~ YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT ED~~R~~W~~N~~KPQKT KGHRGRHIMN GH\*

**vif-T39.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHY VS~~K~~AKKWFY RHHYDSPHPK  
VSSEVH~~I~~PLG DARLEITTYW GLHAGERDW~~H~~ LGQGV~~S~~IEWR KRRYSTHVDP



## FIGURE 7E

DLADQLIHL YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDWINKPQKT KGHRGSHIMN GH\*

**vif-T4.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHMY VSKKARIWFS RHHYGSHPK  
VCSEVHPILG DARLVITTYW SLHAGE\*DWH VGORVSIEWR KRRYSTQVDP  
DLADQLIHL YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDWINKPQKT KGHRGSHIMN GH\*

**vif-T40.pep**

MENRWQVMIV WQVDRMTIRA WNSLVKHHMY VSKKAKKWFY RHHYESPHPK  
VSSEVHPILG DARLVITTYW GLHAGERDWH LGQGVSIWR KRRYSTQVDP  
DLADQLIHL YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDWINKPQKT KGHRGSHIMN GH\*

**vif-T42.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHMY VSKKAKKWFN RHHYDRPHPK  
VSSEVHPILG DARLEITIIFW GLHAGERDWH LGQGVSIWR KRRYSTQVDP  
DLADQLIHL YFDCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDWINKPQKT KGTEGAIQ\*



## FIGURE 7F

**Vif-T43.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHMF VSKKAKKWFY RHHYESPHPK  
VSSEVHIPLG DARLEITTFW GLHAGERDWH LGQGVSIWR KRRYSTQVDP  
DLADQLIHLY YFGCFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLGL  
AALITPKKIK PPLPSVRKLT EDRWNKPQKT KGHRGSHIMN GH\*

**vif-T44.pep**

MENRWQVMIV WQVDRMRIRA WNSLVKHHMY VSKKAKKWFY RHHYESPHHQ  
VSSEVHIPLG DARLEITTYW GLHAGERDWH LGQGVSIWR KRRYSTQVDP  
DLADQLIHLY YFDGFSESAI RKAILGYRVS PRCEYQAGHN KVGSLQYLAL  
AALITPKKIK PPLPSVRKLT EDRWNKPQKT KGHRGSHIMN GH\*



## FIGURE 8A

N13 (SEQ ID NO:27)

ATGGAAAACAGATGGCAGGTGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAACATGGAACAGTTAGAAAATACCATATGTATTGATCAAAGAAAGCTAGGAAATGGTTTATTGACATCACTATCAAAGTCCTCATCCAAAAGTAAGTTAGAAGTACACATCCCACTAGAGGATGCTAGATTGAAATAACATCATTGGGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGAGATATAGCACAACAGTCGACCCCTGATCTAGCAGACCAACTAATTCTGTATTATTTGATTGTTTCAGAATCTGCTATAAGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGACATAGCAAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAGCCACCTTGCGAGTGTCAAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N15 (SEQ ID NO:28)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAACATGGAACAGTTAGAAAATACCATATGTATAGATCAAAGAAAGCTAGGAAATGGTTTATAGACATCACTATCAAAGTCCTCATCCAAAGAGTAAGTTAGAAGTACACATCCCACTAGAGGATGCTAGATTGAAATAACAACATATTGGGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGAGATATAGCACAAGTAGACCCCTGATCTAGCAGACCAACTAATTCTGTATTATTTGATTGTTTCAGAATCTGCTATAAGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGACATAGCAAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAGCCACCTTGCGAGTGTCAAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N17 (SEQ ID NO:29)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAACATGGAACAGTTAGAAAATACCATATGTATAGATCAAAGAAAGCTAGGAAATGGTTTATAGACATCACTATCAAAGTCCTCATCCAAAAGTAAGTTAGAAGTACACATCCCACTAGAGGATGCTAGATTGAAATAACAACATATTGGGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGAGATATAGCACAAGTAGACCCCTGATCTAGCAGACCAACTAATTCTGTATTATTTGATTGTTTCAGAATCTGCTATAAGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGACATAGCAAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAGCCACCTTGCGAGTGTCAAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N22 (SEQ ID NO:30)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAACATGGAACAGTTAGTAACATACCATATGTATAGATCACAGAAAGCTAGGAAATGGTTTATAGACATCACTATCACAGTCCTCATCCAAAAGTAAGTTAGAAGTCCACATCCCACTAGAGGATGCTAGATTGCAATAACACATTGGGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGAGATATAGCACAAGTAGACCCCTGATCTAGCAGACCAACTAATTCTGTATTATTTGATTGTTTCAGAATCTGCTATAAGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGACATAGCAAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAGCCACCTTGCGAGTGTCAAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG



## FIGURE 8B

N23 (SEQ ID NO:31)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAGGTAGACAGGGATGAGGATTAGAACA  
 TGGAACAGTTAGTAAAATACCATATGTATAGATCAAAGAAAGCTAGGGAATGGTTTAT  
 AGACATCACTATCAAAGTCTCATCCAAAAGTAAGTTCAGAAGTCCACATCCCCTAGAG  
 GATGCTAGATTGGAAATAACAACATATTGGGGTCTGCATACAGGAGAAAGAGACTGGCAT  
 TTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGGAGATATAGCACACACAGTCGACCC  
 GATCTCGCAGACCACCTAATTCTGTGTTATTGATTGTCTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGACACAGAGTTAGTCCCTAGGTGTGAATATCGAGCAGGACATAGC  
 AAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAG  
 CCACCTTGGCGAGTGTCAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N24 (SEQ ID NO:32)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAGGTAGACAGGGATGAGGATTAGAACA  
 TGGAACAGTTAGTAAAATACCATATGTATAGATCAAAGAAAGCTAGGGAATGGTTTAT  
 AGACATCACTATCAAAGTCTCATCCAAAAGTAAGTTCAGAAGTACACATCCCCTAGAG  
 GATGCTAGATTGGTAATAACAACATATTGGGGTCTGCATACAGGAGAAAGAGACTGGCAT  
 TTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGGAGATATAGCACACACAGTCGACCC  
 GATCTAGCAGACCACCTAATTCTGTGTTATTGATTGTCTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGACACAGAGTTAGTCCCTAGGTGTGAATATCGAGCAGGACATAGC  
 AAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAG  
 CCACCTTGGCGAGTGTCAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N26 (SEQ ID NO:33)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAGGTAGACAGGGATGAGGATTAGAACA  
 TGGAACAGTTAGTAAAATACCATATGTATAGATCAAAGAAAGCTAGGGAATGGTTTAT  
 AGACATCACTATCAAAGTCTCATCCAAAAGTAAGTTCAGAAGTACACATCCCCTAGAG  
 GATGCTAGATTGGTAATAACAACATATTGGGGTCTGCATACAGGAGAAAGAGACTGGCAT  
 TTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGGAGATATAGCACACACAGTCGACCC  
 GATCTAGCAGACCACCTAATTCTGTGTTATTGATTGTCTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGACACAGAGTTAGTCCCTAGGTGTGAATATCGAGCAGGACATAGC  
 AAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAG  
 CCACCTTGGCGAGTGTCAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N27 (SEQ ID NO:34)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAGGTAGACAGGGATGAGGATTAGAACA  
 TGGAACAGTTAGTAAAATACCATATGTATAGATCAAAGAAAGCTAGGGAATGGTTTAT  
 AGACATCACTATCAAAGTCTCATCCAAAAGTAAGTTCAGAAGTACACATCCCCTAGAG  
 GATGCTAGATTGGTAATAACAACATTTGGGGTCTGCATACAGGAGAAAGAGACTGGCAT  
 TTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAAGGGAGATATAGCACACACAGTCGACCC  
 GATCTAGCAGACCACCTAATTCTGTGTTATTGATTGTCTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGACACAGAGTTAGTCCCTAGGTGTGAATATCGAGCAGGACATAGC  
 AAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAATAACACCAAAAAAGATAAAG  
 CCACCTTGGCGAGTGTCAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGGTCACAGAGGGAGCCATACAATGAATGGACACTAG



## FIGURE 8C

N29 (SEQ ID NO:35)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAAC  
 TGGAACAGTTAGTAAAATACCATATGTATAGATCAAAGAAAGCTAGGGAATGGTTAAT  
 AGACATCACTATCACCGTCCTCATCCAAAAGTAAGTTAGAAGTCCACATCCCACTAGAG  
 GATGCTAGATTGAAATAACAACATTGGGGCTGCATACAGGAGAAAGAGACTGGCAT  
 TTGGGTAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GATCTAGCAGACCAACTAATTCACTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGACATAGC  
 AAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAACACCAAAAAAGATAAAG  
 CCACCTTGCCGAGTGTCAAGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

N30 (SEQ ID NO:36)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAGGTAGACAGGGATGAGGATTAGAAC  
 TGGAACAGTTAGTAAAATACCATATGTATTGATCAAAGAAAAGAAAGGAAATGGT  
 TTTAGACATCACTATCACAGCCCTCATCCAGAACAAAGTTCAACAGCCCACATCCCGC  
 TAGTGGATGGTAGATTGGAAAAAAATAGCAGTTGGAGTCTGGATAACAGGAGATGGCGTCT  
 GGCACAGGGGCATCGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAG  
 ACCCTGATCTAGTAGACCAACTAATTCACTGTATTATTTGATTGTTTCAGAATCTG  
 CTATAAGAAAAGCCATATTAGGACACAGAGTTAGTCCTAGGTGTGAATATCGAGCAGGAC  
 ATAGCAAGGTAGGATCACTACAGTACTTGGCAATAGCAGCATTAAACACCAAAAAAGA  
 TAAAGCCACCTTGCCGAGTGTCAAGAAACTGACAGAGGATAGATGGAACAAGCCCCAGA  
 AGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T3 (SEQ ID NO:37)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGGATGAGGATTAGAAC  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAAAGTAAGTTCAACAGCCCACATCCCGTAGGG  
 GATGGTAGATTGGAGAAAACAGCAGTTGGAGTCTGCAGGCAGGAGATGGAGTCTGGCAC  
 AGGGGGCATCCAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GATTGGTAGACCAACTAATTCACTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T4 (SEQ ID NO:38)

ATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAGGACATGGTTTCT  
 AGACATCACTATGAAAGCCCTCATCCAAAAGTAAGTTCAAGTACACATCCCACTAGGG  
 GATGCTAGATTGGTAGATAACAACATATTGGAGTCTGCATGCAGGAGAATGAGACTGGCAT  
 GTGGGTAGAGACTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GACTTGGCAGACCAACTAATTCACTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAACACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG



## FIGURE 8D

T35 (SEQ ID NO:39)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAAACAGTTAGTAAACACCATATTTTCAAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAACGTAAGTTAGAAGTACACATCCCCTAGGG  
 GATGCTAGATTGGTACAACACCATATTGGGTCTGCATGGAGGAGAAAGAGACTGGTAT  
 CTGGCTCAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCT  
 GACCTGGCAGACCAACTAATTCTGTATTATTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T37 (SEQ ID NO:40)

ATGGAAAACAGATGGGAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAAACAGTTAGTAAACACCATATGTATGTTCAAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAAGTAAGTTAGAAGTACACATCCCCTAGGG  
 GATGCTAGATTGGTATAACACCATATTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGGTAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCT  
 GACCTGGCAGACCAACTAATTCTGTATTATTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T38 (SEQ ID NO:41)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAAACAGTTAGTAAACACCATATGTATGTTCAAAAGAAACGCTAAGAAATGGTTTAT  
 CGACATCACTATGACAGCCCTCATCCAGTCAAAGTCAACAGCCCACATCCCCTAGGG  
 GATGGTAGATTGCAGAAAATAGCATTGGAGTCTGGATGCAGGAGAAAGAGACTGGCAT  
 TTGGGTAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCT  
 GACCTGGCAGACCAACTAATTCTGTATTATTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGGCACAGAGGGAGGCATACAATGAATGGACACTAG

T39 (SEQ ID NO:42)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAAACAGTTAGTAAACACCATATGTATGTTCAAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGACAGCCCTCATCCAAAGTAAGTTAGAAGTACACATCCCCTAGGG  
 GATGCTAGATTGGAGATAACACCATATTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGGTAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACACGTTAGACCCT  
 GACCTGGCAGACCAACTAATTCTGTATTATTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTACAGTACTTGGCACTAGCAGCATTAAACACCAAAGAAGATAAAG  
 CCACCTTGCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG



## FIGURE 8E

T40 (SEQ ID NO:43)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGACGATTAGAGCA  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAAAGTAAGTTCAAAGTAGTACACATCCCACTAGGG  
 GATGCTAGATTGGTGTGATAACACATATTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGGTCAAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GACTTGGCAGACCAACTAACTCATCTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAATAACACCAAAAGAAGATAAAG  
 CCACCTTGCCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T42 (SEQ ID NO:44)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGACCGCCCTCATCCAAAAGTAAGTTCAAAGTAGTCCACATCCCACTAGGG  
 GATGCTAGATTGGAGATAACACATTTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGTCAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GACTTGGCAGACCAACTAACTCATCTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAATAACACCAAAAGAAGATAAAG  
 CCACCTTGCCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T43 (SEQ ID NO:45)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAAAGTAAGTTCAAAGTAGTACACATCCCACTAGGG  
 GATGCTAGATTGGAGATAACACATTTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGTCAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GACCTGGCAGACCAACTAATTCTCATCTGTATTATTTGGTTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAATAACACCAAAAGAAGATAAAG  
 CCACCTTGCCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG

T44 (SEQ ID NO:46)

ATGGAAAACAGATGGCAGGTGATGATTGTGGCAAGTAGACAGGGATGAGGATTAGAGCA  
 TGGAACAGTTAGTAAAACACCATATGTATGTTCAAAGAAAGCTAAGAAATGGTTTAT  
 AGACATCACTATGAAAGCCCTCATCCAAAAGTAAGTTCAAAGTAGTACACATCCCACTAGGG  
 GATGCTAGATTGGAGATAACACATATTGGGTCTGCATGCAGGAGAAAGAGACTGGCAT  
 TTGGTCAGGGAGTCTCCATAGAATGGAGGAAAGGAGATATAGCACACAAGTAGACCCCT  
 GACCTGGCAGACCAACTAATTCTCATCTGTATTATTTGATTGTTTCAGAATCTGCTATA  
 AGAAAAGCCATATTAGGATATAGAGTTAGTCCTAGGTGTGAATACCAAGCAGGACATAAT  
 AAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAAATAACACCAAAAGAAGATAAAG  
 CCACCTTGCCCTAGTGTGAGGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACC  
 AAGGCCACAGAGGGAGCCATACAATGAATGGACACTAG



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/19478

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/134.1, 139.1, 148.1, 160.1, 184.1, 188.1, 199.1, 208.1; 435/69.3, 236; 530/350, 324, 387.1, 389.4; 536/23.1, 23.72

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS, BIOSIS, MEDLINE, APS, and BIOTECHNOLOGY

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MA, X.Y. et al. Cysteine Residues in the Vif Protein of Human Immunodeficiency Virus Type 1 Are Essential for Viral Infectivity. Journal of Virology. March 1994, Vol 68, No. 3, pages 1714-1720, see entire document.	1-20
Y	YANG, X. et al. Phosphorylation of Vif and Its Role in HIV-1 Replication. The Journal of Biological Chemistry. 26 April 1996, Vol 271, No. 17, pages 10121-10129, see entire document.	1-20

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
10 JANUARY 1999	28 JAN 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer LAURIE SCHEINER Telephone No. (703) 308-0196
Facsimile No. (703) 305-3230	



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/19478

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 39/40, 39/42, 39/38, 39/21, 39/12, 39/395; C07H 21/02, 21/04, C07K 1/00, 16/00; C12P 21/06, C12N 7/04

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/134.1, 139.1, 148.1, 160.1, 184.1, 188.1, 199.1, 208.1; 435/69.3, 236; 530/350, 324, 387.1, 389.4; 536/23.1, 23.72



## SEQUENCE LISTING

<110> Ayyavoo, Velpandi  
Nagashunmugam, Thandavarayan  
Weiner, David B.  
University of Pennsylvania

<120> ATTENUATED VIF DNA IMMUNIZATION CASSETTES FOR GENETIC  
VACCINES

<130> UPAP-0263

<140> HEREWITH

<141> 1998-09-18

<160> 46

<170> PatentIn Ver. 2.0

<210> 1

<211> 190

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 1

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Lys Ala Arg Trp Phe Tyr Arg His His Tyr Glu Ser Pro His Pro  
35 40 45

Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu Glu  
50 55 60

Thr Thr Thr Tyr Trp Gly Leu His Gly Glu Arg Asp Trp His Leu Gly  
65 70 75 80



Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr Gln Val  
85 90 95

Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe Asp Cys  
100 105 110

Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg Val Ser  
115 120 125

Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser Leu Gln  
130 135 140

Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys Pro Pro  
145 150 155 160

Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys Pro Gln  
165 170 175

Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190

<210> 2

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 2

gaaagcttat ggaaaacaga tggcag 26

<210> 3

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 3

gcaaagctt cattgtatgg ctc 23

<210> 4



&lt;211&gt; 190

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 4

Met Glu Asn Arg Trp Gln Val Ile Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Ser Lys  
20 25 30

Lys Ala Arg Glu Trp Phe Tyr His His Tyr Gln Ser Pro His Pro Lys  
35 40 45

Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu Glu Ile  
50 55 60

Thr Ser Phe Trp Gly Leu His Thr Gly Glu Arg Asp Trp His Leu Gly  
65 70 75 80

Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr His Val  
85 90 95

Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe Asp Cys  
100 105 110

Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg Val Ser  
115 120 125

Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser Leu Gln  
130 135 140

Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys Pro Pro  
145 150 155 160

Leu Ala Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys Pro Gln  
165 170 175

Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 5

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 5

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His  
35 40 45Pro Arg Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60Glu Ile Thr Thr Tyr Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 6

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 6

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met

1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser

20 25 30

Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His

35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu

50 55 60

Glu Thr Thr Thr Tyr Trp Gly Leu His Thr Gly Glu Arg Asp Trp His

65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr

85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe

100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg

115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser

130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys

145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys

165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His

180 185 190



&lt;210&gt; 7

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 7

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Thr Tyr His Met Tyr Arg Ser  
20 25 30

Gln Lys Ala Arg Glu Trp Phe Asn Arg His His Tyr His Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60

Ala Ile Pro Thr Phe Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 8

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 8

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30

Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60

Glu Ile Thr Thr Tyr Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

His Val Asp Pro Asp Leu Ala Asp His Leu Ile His Leu Cys Tyr Phe  
100 105 110

Asp Cys Leu Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 9

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 9

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30

Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60

Val Ile Thr Thr Tyr Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

His Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Ala Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 10

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 10

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His  
35 40 45Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60Val Ile Thr Thr Tyr Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95Gln Val Asp Pro Asp Leu Ala Asp His Leu Ile His Leu Tyr Tyr Phe  
100 105 110Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160Pro Pro Leu Ala Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 11

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 11

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30

Lys Lys Ala Arg Glu Trp Phe Tyr Arg His His Tyr Gln Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60

Val Ile Thr Thr Phe Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

His Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 12

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 12

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser  
20 25 30

Lys Lys Ala Arg Glu Trp Phe Asn Arg His His Tyr His Arg Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Glu Asp Ala Arg Leu  
50 55 60

Glu Ile Thr Thr Phe Trp Gly Leu His Thr Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 13

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 13

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met

1 5 10

15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys Tyr His Met Tyr Arg Ser

20

25

30

Gln Lys Glu Arg Glu Trp Phe Asn Arg His His Tyr His Ser Pro His

35

40

45

Pro Glu Gln Ser Ser Thr Ala His Ile Pro Leu Val Asp Gly Arg Leu

50

55

60

Glu Lys Ile Ala Val Trp Ser Leu Asp Thr Gly Glu Gly Val Trp His

65

70

75

80

Arg Gly His Arg Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr

85

90

95

Gln Val Asp Pro Asp Leu Val Asp Gln Leu Ile His Leu Tyr Tyr Phe

100

105

110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly His Arg

115

120

125

Val Ser Pro Arg Cys Glu Tyr Arg Ala Gly His Ser Lys Val Gly Ser

130

135

140

Leu Gln Tyr Leu Ala Ile Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys

145

150

155

160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys

165

170

175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His

180

185

190



&lt;210&gt; 14

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 14

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Thr Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Glu Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Thr Ala His Ile Pro Leu Gly Asp Gly Arg Leu  
50 55 60

Glu Lys Thr Ala Val Trp Ser Leu Gln Ala Gly Asp Gly Val Trp His  
65 70 75 80

Arg Gly His Pro Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Val Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 15

&lt;211&gt; 191

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 15

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30Lys Lys Ala Arg Thr Trp Phe Ser Arg His His Tyr Gly Ser Pro His  
35 40 45Pro Lys Val Cys Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu  
50 55 60Val Ile Thr Thr Tyr Trp Ser Leu His Ala Gly Glu Asp Trp His Val  
65 70 75 80Gly Gln Arg Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr Gln  
85 90 95Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe Asp  
100 105 110Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg Val  
115 120 125Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser Leu  
130 135 140Gln Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys Pro  
145 150 155 160Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys Pro  
165 170 175Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 16

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 16

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Thr Tyr Phe Ser  
20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Glu Ser Pro His  
35 40 45

Pro Asn Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu  
50 55 60

Val Thr Thr Pro Tyr Trp Gly Leu His Gly Gly Glu Arg Asp Trp Tyr  
65 70 75 80

Leu Ala Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 17

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 17

Met Glu Asn Arg Trp Glu Val Met Ile Val Trp Glu Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Glu Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu  
50 55 60

Val Ile Thr Thr Tyr Trp Gly Leu His Ala Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110


Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 18

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 17

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Asn Ala Lys Lys Trp Phe Tyr Arg His His Tyr Asp Ser Pro His  
35 40 45

Pro Val Gln Ser Ser Thr Ala His Ile Pro Leu Gly Asp Gly Arg Leu  
50 55 60

Gln Lys Ile Ala Phe Trp Ser Leu Asp Ala Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Arg His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 19

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 19

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Asp Ser Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu  
50 55 60

Glu Thr Thr Thr Tyr Trp Gly Leu His Ala Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

His Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gin Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His  
180 185 190



&lt;210&gt; 20

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 20

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met

1 5 10 15

Thr Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser

20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Glu Ser Pro His

35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu

50 55 60

Val Ile Thr Thr Tyr Trp Gly Leu His Ala Gly Glu Arg Asp Trp His

65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr

85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Thr His Leu Tyr Tyr Phe

100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg

115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser

130 135 140

Leu Gln Tyr Leu Ala Leu Ala Leu Ile Thr Pro Lys Lys Ile Lys

145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys

165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His

180 185 190



&lt;210&gt; 21

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 21

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met  
1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Tyr Val Ser  
20 25 30

Lys Lys Ala Lys Lys Trp Phe Asn Arg His His Tyr Asp Arg Pro His  
35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu  
50 55 60

Glu Ile Thr Thr Phe Trp Gly Leu His Ala Gly Glu Arg Asp Trp His  
65 70 75 80

Leu Gly Gln Arg Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr  
85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Thr His Leu Tyr Tyr Phe  
100 105 110

Asp Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg  
115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser  
130 135 140

Leu Gln Tyr Leu Ala Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys  
145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys  
165 170 175

Pro Gln Lys Thr Lys Gly Thr Glu Gly Ala Ile Gln  
180 185



&lt;210&gt; 22

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 22

Met Glu Asn Arg Trp Gln Val Met Ile Val Trp Gln Val Asp Arg Met

1 5 10 15

Arg Ile Arg Ala Trp Asn Ser Leu Val Lys His His Met Phe Val Ser

20 25 30

Lys Lys Ala Lys Lys Trp Phe Tyr Arg His His Tyr Glu Ser Pro His

35 40 45

Pro Lys Val Ser Ser Glu Val His Ile Pro Leu Gly Asp Ala Arg Leu

50 55 60

Glu Ile Thr Thr Phe Trp Gly Leu His Ala Gly Glu Arg Asp Trp His

65 70 75 80

Leu Gly Gln Gly Val Ser Ile Glu Trp Arg Lys Arg Arg Tyr Ser Thr

85 90 95

Gln Val Asp Pro Asp Leu Ala Asp Gln Leu Ile His Leu Tyr Tyr Phe

100 105 110

Gly Cys Phe Ser Glu Ser Ala Ile Arg Lys Ala Ile Leu Gly Tyr Arg

115 120 125

Val Ser Pro Arg Cys Glu Tyr Gln Ala Gly His Asn Lys Val Gly Ser

130 135 140

Leu Gln Tyr Leu Gly Leu Ala Ala Leu Ile Thr Pro Lys Lys Ile Lys

145 150 155 160

Pro Pro Leu Pro Ser Val Arg Lys Leu Thr Glu Asp Arg Trp Asn Lys

165 170 175

Pro Gln Lys Thr Lys Gly His Arg Gly Ser His Thr Met Asn Gly His

180 185 190



&lt;210&gt; 23

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 23

Met	Glu	Asn	Arg	Trp	Gln	Val	Met	Ile	Val	Trp	Gln	Val	Asp	Arg	Met
1	5					10						15			

Arg	Ile	Arg	Ala	Trp	Asn	Ser	Leu	Val	Lys	His	His	Met	Tyr	Val	Ser
	20				25						30				

Lys	Lys	Ala	Lys	Lys	Trp	Phe	Tyr	Arg	His	His	Tyr	Glu	Ser	Pro	His
35					40						45				

Pro	Gln	Val	Ser	Ser	Glu	Val	His	Ile	Pro	Leu	Gly	Asp	Ala	Arg	Leu
50					55				60						

Glu	Ile	Thr	Thr	Tyr	Trp	Gly	Leu	His	Ala	Gly	Glu	Arg	Asp	Trp	His
65				70			75				80				

Leu	Gly	Gln	Gly	Val	Ser	Ile	Glu	Trp	Arg	Lys	Arg	Arg	Tyr	Ser	Thr
	85				90						95				

Gln	Val	Asp	Pro	Asp	Leu	Ala	Asp	Gln	Leu	Ile	His	Leu	Tyr	Tyr	Phe
	100				105					110					

Asp	Cys	Phe	Ser	Glu	Ser	Ala	Ile	Arg	Lys	Ala	Ile	Leu	Gly	Tyr	Arg
	115				120					125					

Val	Ser	Pro	Arg	Cys	Glu	Tyr	Gln	Ala	Gly	His	Asn	Lys	Val	Gly	Ser
	130				135					140					

Leu	Gln	Tyr	Leu	Ala	Leu	Ala	Ala	Leu	Ile	Thr	Pro	Lys	Lys	Ile	Lys
145					150			155		160					

Pro	Pro	Leu	Pro	Ser	Val	Arg	Lys	Leu	Thr	Glu	Asp	Arg	Trp	Asn	Lys
					165			170			175				

Pro	Gln	Lys	Thr	Lys	Gly	His	Arg	Gly	Ser	His	Thr	Met	Asn	Gly	His
	180				185					190					



<210> 24

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 24

Ile Glu Trp Arg Lys Lys Arg Tyr

1 5

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 25

Asp Arg Trp Asn Lys Pro Gln

1 5

<210> 26

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 26

Ser Leu Gln Tyr Leu Ala

1 5

<210> 27

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 27



atggaaaaca gatggcaggt gattattgtg tggcaggtag acaggatgag gattagaaca 60  
tggaacagtt tagtaaaaata ccatatgtat tgcataaaga aagctaggaa atggtttat 120  
tgacatcaact atcaaagtcc tcatccaaaa gtaagttcag aagtacacat cccactagag 180  
gatgctagat tggaaataac atcatttgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atgcacaca cgtcgaccct 300  
gatctagcag accaactaat tcacatgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggaca cagagttgt cctaggtgt aatatcgagc aggacatagc 420  
aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
ccacccttgg cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggccaca gaggagcca tacaatgaat ggacactag 579

<210> 28

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 28

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggaacagtt tagtaaaaata ccatatgtat agatcaaaga aagctaggaa atggtttat 120  
agacatcaact atcaaagtcc tcatccaaaa gtaagttcag aagtacacat cccactagag 180  
gatgctagat tggaaataac aacatattgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atgcacaca agtagaccct 300  
gatctagcag accaactaat tcacatgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggaca cagagttgt cctaggtgt aatatcgagc aggacatagc 420  
aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
ccacccttgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggccaca gaggagcca tacaatgaat ggacactag 579

<210> 29

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 29

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggaacagtt tagtaaaaata ccatatgtat agatcaaaga aagctaggaa atggtttat 120  
agacatcaact atcaaagtcc tcatccaaaa gtaagttcag aagtacacat cccactagag 180  
gatgctagat tggaaataac aacatattgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atgcacaca agtagaccct 300



gatctagcag accaactaat tcatctgtat tattttgatt gttttcaga atctgctata 360  
 agaaaaagcca tattaggaca cagagtttagt cctaggtgtg aatatcgagc aggacatagc 420  
 aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
 ccacctttgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gaggagcca tacaatgaat ggacactag 579

&lt;210&gt; 30

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 30

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
 tggAACAGTT tagtaacata ccatacgat agatcacaga aagctaggaa atggtttaat 120  
 agacatcact atcacagtcc tcatccaaaa gtaagttcag aagtccacat cccactagag 180  
 gatcttagat tggcaatacc aacatTTGG ggtctgcata caggagaaag agactggcat 240  
 ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
 gatctagcag accaactaat tcatctgtat tattttgatt gttttcaga atctgctata 360  
 agaaaaagcca tattaggaca cagagtttagt cctaggtgtg aatatcgagc aggacatagc 420  
 aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
 ccacctttgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gaggagcca tacaatgaat ggacactag 579

&lt;210&gt; 31

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 31

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
 tggAACAGTT tagtaaaaata ccatacgat agatcaaaga aagctaggaa atggttttat 120  
 agacatcact atcaaagtcc tcatccaaaa gtaagttcag aagtccacat cccactagag 180  
 gatcttagat tggaaataac aacatattgg ggtctgcata caggagaaag agactggcat 240  
 ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca cgtcgaccct 300  
 gatctcgac accaccata tcatctgtt tattttgatt gtcttcaga atctgctata 360  
 agaaaaagcca tattaggaca cagagtttagt cctaggtgtg aatatcgagc aggacatagc 420  
 aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
 ccacctttgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gaggagcca tacaatgaat ggacactag 579



<210> 32

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 32

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggAACAGTT tagtaaaaata ccataatgtat agatcaaaga aagcttaggga atggTTTAT 120  
agacatcaCT atcaaAGTCC tcATCCAAA gtaagttcag aagtacacat cccactagag 180  
gatgctAGAT tggtaataac aacatattgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca cgtagaccct 300  
gatctAGCAG accaactaat tcATCTGTAT tattttgatt gttttcaga atctgctata 360  
agaaaAGCCA tattaggaca cagagttagt cctaggtgtg aatatcgagc aggacatagc 420  
aaggttaggat cactacAGTA ctggcaata gcagcattaa taacaccaaa aaagataaag 480  
ccacCTTGG CGAGTGTAG gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aaggGCCACA gagggagCCA tacaatGAAT ggacactag

579

<210> 33

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 33

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggAACAGTT tagtaaaaata ccataatgtat agatcaaaga aagcttaggga atggTTTAT 120  
agacatcaCT atcaaAGTCC tcATCCAAA gtaagttcag aagtacacat cccactagag 180  
gatgctAGAT tggtaataac aacatattgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gatctAGCAG accaccaaat tcATCTGTAT tattttgatt gttttcaga atctgctata 360  
agaaaAGCCA tattaggaca cagagttagt cctaggtgtg aatatcgagc aggacatagc 420  
aaggttaggat cactacAGTA ctggcaata gcagcattaa taacaccaaa aaagataaag 480  
ccacCTTGG CGAGTGTAG gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aaggGCCACA gagggagCCA tacaatGAAT ggacactag

579

<210> 34

<211> 579

<212> DNA

<213> Artificial Sequence



&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 34

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggAACAGTT tagtaaaaata ccatagtat agatcaaaga aagctaggga atggTTTAT 120  
agacatcaat atcaaagtcc tcatccaaaa gtaagttcag aagtacacat cccactagag 180  
gatgctagat tggtaataac aacattttgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca cgtagaccct 300  
gatctagcag accaactaat tcacTgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggaca cagagttagt cctaggtgtg aatatcgagc aggacatagc 420  
aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
ccacccTTgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggtcaca gagggagcca tacaatgaat ggacactag 579

&lt;210&gt; 35

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 35

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60  
tggAACAGTT tagtaaaaata ccatagtat agatcaaaga aagctaggga atggTTTAT 120  
agacatcaat atcaccgtcc tcatccaaaa gtaagttcag aagtccacat cccactagag 180  
gatgctagat tggaaataac aacattttgg ggtctgcata caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gatctagcag accaactaat tcacTgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggaca cagagttagt cctaggtgtg aatatcgagc aggacatagc 420  
aaggttaggat cactacagta ctggcaata gcagcattaa taacacccaa aaagataaag 480  
ccacccTTgc cgagtgtcag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggtcaca gagggagcca tacaatgaat ggacactag 579

&lt;210&gt; 36

&lt;211&gt; 584

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 36

atggaaaaca gatggcaggt gatgattgtg tggcaggtag acaggatgag gattagaaca 60



tggAACAGTTAGTAAAATA CCAATATGTAT TGTCAAAGAA AAAGAAAGAA AGGGAATGGT 120  
 TTATAGACATCACTATCAC AGCCCTCATC CAGAACAAAG TTCAACAGCC CACATCCCGC 180  
 TAGTGGATGGTAGATTGGAA AAAATAGCAG TTGGAGTCAGGATACAGGA GATGGCGTCT 240  
 GGCACAGGGGG GCATCGAGTC TCCATAGAAAT GGAGGAAAAG GAGATATAGC ACACAAGTAG 300  
 ACCCTGATCT AGTAGACCAA CTAATTATC TGTATTATTT TGATTGTTT TCAGAATCTG 360  
 CTATAAGAAA AGCCATATTA GGACACAGAG TTAGTCCTAG GTGTGAATAT CGAGCAGGAC 420  
 ATAGCAAGGT AGGATCACTA CAGTACTTGG CAATAGCAGC ATTAATAACA CCAAAAAAGA 480  
 TAAAGCCACC TTGCGGAGT GTCAGGAAAC TGACAGAGGA TAGATGGAAC AAGCCCCAGA 540  
 AGACCAAGGGG CCACAGAGGG AGCCATACAA TGAATGGACA CTAG 584

&lt;210&gt; 37

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 37

ATGGAAAACA GATGGCAGGT GATGATTGTG TGGCAAGTAG ACAGGATGAG GATTAGAAC 60  
 TGGAACAGTTAGTAAAACA CCAATATGTAT GTTCAAAGAA AAGCTAAGAA ATGGTTTAT 120  
 AGACATCACT ATGAAAGCCC TCACTAAAAA GTAAGTCAA CAGCCCACAT CCCGCTAGGG 180  
 GATGGTAGAT TGGAGAAAAC AGCAGTTGG AGTCTGCAGG CAGGAGATGG AGTCTGGCAC 240  
 AGGGGGCATIC CAGTCTCCAT AGAATGGAGG AAAAGGAGAT ATAGCACACAA AGTAGACCT 300  
 GATTGGTAG ACCAACTAAT TCACTGTAT TATTTGATT GTTTTCAGA ATCTGCTATA 360  
 AGAAAAGCCA TATTAGGATA TAGAGTTAGT CCTAGGTGTG AATACCAAGC AGGACATAAT 420  
 AAGGTTAGGAT CTCTACAGTA CTGGCACTA GCAGCATTAA TAACACCAAA GAAGATAAAG 480  
 CCACCTTGC CTAGTGTAG GAAACTGACA GAGGATAGAT GGAACAAGCC CCAGAAGACC 540  
 AAGGGCCACA GAGGGAGCCA TACAATGAAT GGACACTAG 579

&lt;210&gt; 38

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 38

ATGGAAAACA GATGGCAGGT GATGATTGTG TGGCAAGTAG ACAGGATGAG GATTAGAGCA 60  
 TGGAACAGTTAGTAAAACA CCAATATGTAT GTTCAAAGAA AAGCTAGGAC ATGGTTTCT 120  
 AGACATCACT ATGGAAGCCC TCACTAAAAA GTATGTTCAAG AAGTACACAT CCCACTAGGG 180  
 GATGCTAGAT TGGTGTAAAC AACATATTGG AGTCTGCATG CAGGAGAATG AGACTGGCAT 240  
 GTGGGTCAA GAGTCTCCAT AGAATGGAGG AAAAGGAGAT ATAGCACACAA AGTAGACCT 300  
 GACTTGGCAG ACCAACTAAT TCACTGTAT TATTTGATT GTTTTCAGA ATCTGCTATA 360



agaaaaagcca tattaggata tagagtttagt cctaggtgtg aataccaagc aggacataat 420  
 aaggtaggat ctctacagta cttggcacta gcagcattaa taacacccaa gaagataaag 480  
 ccaccttgc ctatgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gagggagcca tacaatgaat ggacactag 579

&lt;210&gt; 39

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 39

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60  
 tggAACAGTT tagtaaaaca ccatattttat ttttcaaaga aagctaagaa atggTTTAT 120  
 agacatcaat atgaaAGCCC tcacccaaac gtaagttcag aagtacacat cccactaggg 180  
 gatgctagat tggtgacaac accatattgg ggtctgcattt gaggagaag agactggat 240  
 ctggctcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
 gacctggcag accaactaat tcacatgtat tattttgattt gttttcaga atctgctata 360  
 agaaaaagcca tattaggata tagagtttagt cctaggtgtg aataccaagc aggacataat 420  
 aaggtaggat ctctacagta cttggcacta gcagcattaa taacacccaa gaagataaag 480  
 ccaccttgc ctatgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gagggagcca tacaatgaat ggacactag 579

&lt;210&gt; 40

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 40

atggaaaaca gatgggaggt gatgattgtg tgggaagtag acaggatgag gattagagca 60  
 tggAACAGTT tagtaaaaca ccatatgtat ttttcaaaga aagctaagaa atggTTTAT 120  
 agacatcaat atgaaAGCCC tcacccaaa gtaagttcag aagtacacat cccactaggg 180  
 gatgctagat tggtgataac aacatattgg ggtctgcattt gaggagaag agactggat 240  
 ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
 gacctggcag accaactaat tcacatgtat tattttgattt gttttcaga atctgctata 360  
 agaaaaagcca tattaggata tagagtttagt cctaggtgtg aataccaagc aggacataat 420  
 aaggtaggat ctctacagta cttggcacta gcagcattaa taacacccaa gaagataaag 480  
 ccaccttgc ctatgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
 aagggccaca gagggagcca tacaatgaat ggacactag 579



<210> 41

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 41

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60  
tggAACAGTT tagtaaaaca ccatatgtat gtttcaaaga acgctaagaa atggTTTAT 120  
cgacatcaat atgacagccc tcatccagtc caaagttcaa cagcccacat cccgctaggg 180  
gatggtagat tgcagaaaat agcatttgg agtctggatg caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gacctggcag accaactaat tcatctgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagtttagt cctaggtgtg aataccaagc aggacataat 420  
aaggtaggat ctctacagta ctggcacta gcagcattaa taacacccaaa gaagataaag 480  
ccacccTTGC ctatgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aaggggcaca gagggaggca tacaatgaat ggacactag 579

<210> 42

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 42

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60  
tggAACAGTT tagtaaaaca ccatatgtat gtttcaaaga aagctaagaa atggTTTAT 120  
agacatcaat atgacagccc tcatccaaaa gtaagttcag aagtacacat cccactaggg 180  
gatgctagat tggagataac aacatattgg ggtctgcattg caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca ctagaccct 300  
gacctggcag accaactaat tcatctgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagtttagt cctaggtgtg aataccaagc aggacataat 420  
aaggtaggat ctctacagta ctggcacta gcagcattaa taacacccaaa gaagataaag 480  
ccacccTTGC ctatgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aaggggcaca gagggaggca tacaatgaat ggacactag 579

<210> 43

<211> 579

<212> DNA

<213> Artificial Sequence



&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 43

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgac gattagagca 60  
tggaaacagtt tagtaaaaca ccatatgtat gttcaaaga aagctaagaa atggtttat 120  
agacatcaat atgaaagccc tcattccaaaa gtaagttcag aagtacacat cccactaggg 180  
gatgctagat tgggtgataac aacatattgg ggtctgcattt caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gacttggcag accaactaac tcattgtat tattttgait gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagttgtt cctaggtgtg aataccaagc aggacataat 420  
aaggttaggat ctctacagta ctggcacta gcagcattaa taacacccaa gaagataaag 480  
ccacccttgc ctatgttgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aaggggccaca gaggagccca tacaatgaat ggacactag 579

&lt;210&gt; 44

&lt;211&gt; 578

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 44

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60  
tggaaacagtt tagtaaaaca ccatatgtat gttcaaaga aagctaagaa atggtttat 120  
agacatcaat atgaccggcc tcattccaaaa gtaagttcag aagtccacat cccactaggg 180  
gatgctagat tggagataac aacatattgg ggtctgcattt caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gacttggcag accaactaac tcattgtat tattttgattt gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagttgtt cctaggtgtg aataccaagc aggacataat 420  
aaggttaggat ctctacagta ctggcacta gcagcattaa taacacccaa gaagataaag 480  
ccacccttgc ctatgttgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggcacag agggagccat acaatgaatg gacactag 578

&lt;210&gt; 45

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Novel Sequence

&lt;400&gt; 45

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60



tggaacagtt tagaaaaca ccatatgtt gttcaaaga aagctaagaa atggtttat 120  
agacatcact atgaaagccc tcatccaaaa gtaagttcag aagtacacat cccactaggg 180  
gatgctagat tggagataac aacatttgg ggtctgcattg caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gacctggcag accaactaat tcatctgtat tattttgtt gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagttgtt cctaggtgtg aataccaagc aggacataat 420  
aaggttaggat ctctacagta ctggacta gcagcattaa taacaccaa gaagataaag 480  
ccaccttgc ctgtgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggccaca gagggagcca tacaatgaat ggacactag 579

<210> 46

<211> 579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 46

atggaaaaca gatggcaggt gatgattgtg tggcaagtag acaggatgag gattagagca 60  
tggaacagtt tagaaaaca ccatatgtat gttcaaaga aagctaagaa atggtttat 120  
agacatcact atgaaagccc tcatccacaa gtaagttcag aagtacacat cccactaggg 180  
gatgctagat tggagataac aacatattgg ggtctgcattg caggagaaag agactggcat 240  
ttgggtcagg gagtctccat agaatggagg aaaaggagat atagcacaca agtagaccct 300  
gacctggcag accaactaat tcatctgtat tattttgatt gttttcaga atctgctata 360  
agaaaagcca tattaggata tagagttgtt cctaggtgtg aataccaagc aggacataat 420  
aaggttaggat ctctacagta ctggacta gcagcattaa taacaccaa gaagataaag 480  
ccaccttgc ctgtgtgag gaaactgaca gaggatagat ggaacaagcc ccagaagacc 540  
aagggccaca gagggagcca tacaatgaat ggacactag 579

RECEIVED  
AT THE  
U.S. PATENT  
AND TRADEMARK  
OFFICE  
ON APRIL 13,  
1999  
10:00 AM  
EST

